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Abstract
Viruses are obligate, intracellular pathogens that hijack host cell machinery to replicate. Innate immunity is the
first line of defense against such perceived threats through recognition of broadly conserved pathogen
signatures. Tetherin (also known as BST2/CD317/HM1.24) is an innate immune factor that senses and
restricts egress, the final step of viral replication. Tetherin potently reduces cell-free virus spread by
indiscriminately “tethering” particles at the cell surface via direct anchoring to the host membrane. The
majority of previous studies on Tetherin focused on elucidating the minimal structural features necessary for
tethering viral particles and understanding how viruses counter Tetherin function. While the cytoplasmic tail
of Tetherin is dispensable for restricting virus release in the absence of certain viral antagonists, our work, in
part, has focused on conserved residues within the tail, hypothesizing these conserved features could provide
insight into previously under-studied biology, including a poorly characterized signaling function. In Chapter
2 we show that human Tetherin can exist as two alternatively translated isoforms [long (l-) and short (s-)]. s-
Tetherin lacks the first 12 amino acids, a difference that confers functional differences. We found s-Tetherin to
be exquisitely resistant to downregulation by the best characterized Tetherin antagonist, HIV-1 Vpu. l-
Tetherin, which is sensitive to Vpu, was shown to be a potent activator of NF-κB. A dual-tyrosine motif,
unique to l-Tetherin, was identified as an important determinant. In Chapter 3 we describe additional
determinants of signaling. Interestingly, we identified compensatory mutations that produce a tyrosine-
independent signaling-competent Tetherin called SY. We demonstrate that SY Tetherin utilizes a similar
signaling pathway as wt Tetherin. We believe this mutant, at the very least, can be used as a tool to further
elucidate how Tetherin engages signaling machinery. Moreover, the identified compensatory changes in the
cytoplasmic tail may be useful in exploring what we hypothesize to be a previously uncharacterized regulatory
motif. In this dissertation, we explored two novel aspects of Tetherin biology. Our understanding of how
Tetherin isoform expression and Tetherin-mediated signaling is regulated could provide mechanisms by
which we can target and enhance immune responses during infection by clinically relevant viruses.
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PREFACE 
 I have always been fascinated with understanding why things exist as they are. Because 
of this curiosity, my two favorite subjects in high school were history and biology. History taught 
me about the events of the past and how WE as society have been shaped in the present. War 
has been at the center of shaping the world, as we know it today. Countless lives sacrificed and 
an innumerable amount of damage both directed and collateral; long-lasting memories ingrained 
in the minds of the survivors with the hope that we learn from the past to progress as a society, 
moving forward toward a better future. 
Biology peaked my interest because of my curiosity of how WE, as individuals, function. 
War between men has shaped the world we live in, but what I found even more remarkable and 
fascinating, is that microscopic wars are constantly being waged within men, with many aspects 
paralleling what we see on actual battlefields. The continual struggle between host and pathogen 
peaked my interest in infectious disease. The inner workings of the immune system and its 
molecular “arms race” with pathogens have provided insight into our evolutionary history. 
Lessons learned from this basic biology has been instrumental in developing treatments to some 
of the most debilitating and deadly maladies, tipping the fulcrum in OUR, the hosts’, favor. 
However, pathogens evolve and find a way to evade host responses. There is a lot of evidence of 
host-pathogen co-evolution, though molecular détente is typically not an immediate option,  
The following work delves into understanding an innate immune factor encoded by our 
cells as part of its arsenal to battle viral infection. This dissertation sought to elucidate previously 
understudied biology of the antiviral factor, Tetherin. Our work has shed light to a previously 
uncharacterized signaling function, which has bettered our understanding of host-pathogen 
interactions. I am thankful for being afforded the opportunity to pursue this work and to develop it 
as my own. Even through the ups and downs, the experience has been extremely enriching and 
humbling. Many thanks again, to those involved directly and indirectly, for allowing this work to 
move forward. 
       x 
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ABSTRACT 
 
INSIGHT INTO TETHERIN-MEDIATED SIGNALING VIA THE DISCOVERY OF A NOVEL 
ISOFORM WITH BIOLOGICALLY DISTINCT PROPERTIES 
Luis J. Cocka 
Paul Bates 
 
Viruses are obligate, intracellular pathogens that hijack host cell machinery to replicate. Innate 
immunity is the first line of defense against such perceived threats through recognition of broadly 
conserved pathogen signatures. Tetherin (also known as BST2/CD317/HM1.24) is an innate 
immune factor that senses and restricts egress, the final step of viral replication. Tetherin potently 
reduces cell-free virus spread by indiscriminately “tethering” particles at the cell surface via direct 
anchoring to the host membrane. The majority of previous studies on Tetherin focused on 
elucidating the minimal structural features necessary for tethering viral particles and 
understanding how viruses counter Tetherin function. While the cytoplasmic tail of Tetherin is 
dispensable for restricting virus release in the absence of certain viral antagonists, our work, in 
part, has focused on conserved residues within the tail, hypothesizing these conserved features 
could provide insight into previously under-studied biology, including a poorly characterized 
signaling function. In Chapter 2 we show that human Tetherin can exist as two alternatively 
translated isoforms [long (l-) and short (s-)]. s-Tetherin lacks the first 12 amino acids, a difference 
that confers functional differences. We found s-Tetherin to be exquisitely resistant to 
downregulation by the best characterized Tetherin antagonist, HIV-1 Vpu. l-Tetherin, which is 
sensitive to Vpu, was shown to be a potent activator of NF-κB. A dual-tyrosine motif, unique to l-
Tetherin, was identified as an important determinant. In Chapter 3 we describe additional 
determinants of signaling. Interestingly, we identified compensatory mutations that produce a 
tyrosine-independent signaling-competent Tetherin called SY. We demonstrate that SY Tetherin 
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utilizes a similar signaling pathway as wt Tetherin. We believe this mutant, at the very least, can 
be used as a tool to further elucidate how Tetherin engages signaling machinery. Moreover, the 
identified compensatory changes in the cytoplasmic tail may be useful in exploring what we 
hypothesize to be a previously uncharacterized regulatory motif. In this dissertation, we explored 
two novel aspects of Tetherin biology. Our understanding of how Tetherin isoform expression and 
Tetherin-mediated signaling is regulated could provide mechanisms by which we can target and 
enhance immune responses during infection by clinically relevant viruses. 
 
   1 
CHAPTER 1: INTRODUCTION TO TETHERIN – AN INTRINSIC RESTRICTION 
FACTOR AND IMMUNE SENSOR OF ENVELOPED VIRUS EGRESS 
 
“All delays are dangerous in war.” – John Dryden 
 
General Overview of Innate Immune Responses to Viral Infection  
Viral sensing by intrinsic immune receptors 
Viruses are highly abundant pathogens in nature that can present a burden to every living 
organism from unicellular bacteria to multicellular plants and animals. Though not considered 
technically alive, viruses share some properties with living things to ensure species survival, 
including genome maintenance across generations and an ability to adapt to the environment. 
Viral replication is contingent on infecting a host cell. However, cells express immune barriers that 
can block essentially every stage of viral replication. This selective pressure, coupled with error-
prone replication machinery, particularly in the case of RNA viruses, drives viral evolution in the 
form of tolerable mutations to escape recognition by both cell-intrinsic and -extrinsic immune 
responses (113, 188, 245). The dynamic “arms race” between host and pathogen has resulted in 
convergent evolution observed in viruses from disparate families that target similar cellular 
immune sensing pathways. Cells constitutively express both cytosolic and membrane-bound 
proteins referred to collectively as pattern recognition receptors (PRRs), which bind conserved 
pathogen signatures. Examples of membrane-bound sensors include the plasma membrane (PM) 
localized Toll-like receptors (TLRs), TLR2 or 4, which have been traditionally described as 
sensors of bacteria-derived products such as bacterial lipopolysaccharide (LPS), and C-type 
lectin receptors (CLRs). Both these families of receptors can also sense viral-encoded structural 
proteins that contain carbohydrate- and lipid-rich moieties (85, 103). Additionally, intracellular 
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TLRs that localize to endosomal membranes, like TLR3, 7 and 9, sense viral nucleic acids (103). 
Additional viral nucleic acid sensors localize to the cytoplasm including the retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLRs), which include RIG-I and melanoma differentiating factor 5 
(MDA5), both of which specifically recognize viral RNAs (29). More recently, cyclic GMP-AMP 
synthase (cGAS) was identified as the cytoplasmic sensor for viral DNA (221). PRR sensing of 
pathogen-derived ligands activates downstream signaling networks that converge and synergize, 
leading to nuclear translocation of various transcription factors that modulate expression of 
proteins involved in immune responses (Figure 1-1). These include members of the nuclear factor 
kappa-light chain-enhancer of activated B cells (NF-κB), interferon regulatory factor (IRF), 
activator protein 1 (AP-1) and signal transducer and activator of transcription (STAT) families 
(212, 266). 
Overview of NF-κB signaling 
NF-κB refers to a superfamily of conserved, rapidly responding transcription factors 
involved in regulating various cell processes including development, cell growth, apoptosis and 
responses to cellular stresses such as infection (80). In mammals, the family is comprised of 5 
members: p65 (RelA), RelB, c-Rel, p105/p50 and p100/p52, which function as either homo- or 
heterodimers with the other members (81). A highly conserved Rel homology domain regulates 
function including dimerization, nuclear translocation, and binding to DNA (151). Generally, the 
NF-κB family members recognize a consensus 10bp DNA sequence, 5′-GGGRNYYYCC-3′ 
(R=purine, Y=pyrimidine, N=any base), in the promoter or enhancer regions of target genes (40). 
Though different family members bind to similar sequences, specific responses are directed by 
cell intrinsic factors in combination with input stimuli. Specificity of the family for particular binding 
sites allows researchers to assess activation using reporter systems (luciferase, GFP, etc.) as a 
surrogate for NF-κB activation. Signaling is tightly regulated: sub optimal activation, in the case of 
infection, may permit pathogen persistence; excessive activation has been associated with 
numerous immunopathologies including cancer and autoimmune disorders as a result of chronic 
inflammation (45, 222).  
       3 
There are two known NF-κB activation pathways: classical and alternative. Classical NF-
κB is ubiquitous, and primarily regulates cellular immune responses, cell growth and death (80, 
81). The alternative signaling pathway is more specific to lymphoid cells and is crucial for 
development in cells of that lineage (48). When the cell is at rest, all NF-κB members are 
sequestered in the cytoplasm and require a proteolytic event for activation and subsequent 
nuclear translocation. In the alternative pathway one half of the NF-κB heterodimer exists as a 
precursor protein, p100, which is bound to RelB (p100/RelB). p100 contains inhibitor domains 
that keeps the dimer cytoplasmic. Nuclear translocation requires proteosomal processing of p100 
to p52, generating the activated p52/RelB heterodimer (207, 253). Classical signaling is primarily 
mediated by the activation of the NF-κB heterodimer p65/p50, which is kept inactive in the 
cytoplasm by NF-κB inhibitor alpha (IκBα) (Figure 1-2). Upon receptor binding/sensing of a 
ligand, a series of phosphorylation events mediate recruitment and activation of downstream 
kinase complexes. Phosphorylation of the Skp, Cullin, F-box containing (SCF) E3 ubiquitin ligase 
complex mediates proteosomal degradation of IκBα, freeing the sequestered NF-κB heterodimer 
to translocate and accumulate in the nucleus where it binds κB sites on the chromosome allowing 
regulation of gene expression (Figure 1-2, (81)).  
NF-κB can be activated by various PRRs, as well as receptors that sense early-secreted 
cytokines like tumor necrosis factor alpha (TNFα). Effector kinases that regulate NF-κB signaling 
also feed into other signaling pathways including the mitogen-activated protein kinase (MAPK) 
pathway to activate additional transcription factors like AP-1, which together with NF-κB regulate 
transcription of various genes involved in cell homeostasis. NF-κB regulates genes involved in 
immune responses, including those that encode cytokines, receptors for direct immune 
recognition and antigen presentation, and factors important for cell transmigration (167). Negative 
regulators of NF-κB signaling, like IκBα, are also regulated by NF-κB, allowing for negative 
feedback to dampen prolonged activation (81, 167). 
NF-κB plays a crucial role during infection, in part, by regulating expression of 
proinflammatory cytokines (114), which are among the earliest danger signals secreted during 
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infection. Acute inflammatory signals are important for recruiting rapidly responding leukocytes 
[e.g. neutrophils, professional antigen presenting cells (APCs) like macrophages and dendritic 
cells (DCs), and natural killer (NK) cells] to the site of damage in order to clear the infectious 
agent and help prime the adaptive immune system (19). Because acute inflammatory responses 
are important early in infection, many viruses encode proteins to subvert activation (117), while 
others have evolved ways to manipulate NF-κB expression to positively regulate replication. 
Certain viruses can activate NF-κB via virally encoded proteins to enhance replication (167). NF-
κB is essential for retroviral replication. In fact, NF-κB was first discovered in studies of human 
immunodeficiency virus 1 (HIV-1) replication (153) where it was identified as a transcription 
factor. Additionally, proinflammatory responses have been suggested to enhance cell targets for 
HIV-1 and other viruses, further promoting infection (142). Conversely, the HIV-1 accessory 
protein viral protein U (Vpu) has been demonstrated to interfere with NF-κB activation by binding 
and sequestering the SCF E3 ligase complex which stabilizes IκBα (28) suggesting HIV-1 needs 
to modulate NF-κB activation to efficiently replicate. Just like the host, chronically infecting viruses 
can modulate the proinflammatory state of a cell to ensure efficient prolonged replication and 
subsequent transmission. Some viruses that cause acute infections, particularly those that 
manifest as hemorrhagic fevers, stimulate uncontrolled cytokine production which causes the 
host to go into shock (166). Elucidating novel NF-κB activating pathways that may directly affect 
viral replication is paramount to not only further our understanding of host-pathogen dynamics, 
but also to identify potential new targets for therapeutics. 
Overview of IFN signaling 
Interferons (IFNs),of which there are three major characterized types (I, II, and III), are a 
second class of cytokine, and like proinflammatory cytokines are also expressed during early 
immune responses. Type I IFNs, primarily α and β, robustly activate the host antiviral state in an 
auto- and paracrine manner through the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signaling pathway, downstream of binding to the IFNα/β receptor 
(IFNAR) (212). IFN signaling activates the innate immune response through upregulation of 
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genes that code for interferon-stimulated genes (ISGs), as well as negative and positive 
regulators of the pathway (Figure 1-1). Through a number of these upregulated ISGs, IFN-
stimulated cells can more readily undergo apoptosis upon viral infection to halt replication (214). 
Moreover, IFNs help prime cells of the adaptive immune system by enhancing T cell effector 
function and enhancing B cell humoral responses (62, 115).  
ISGs present a major hurdle to viral replication across many disparate families (196). 
Viruses can dampen the antiviral response by targeting both direct expression of IFNs and IFN-
mediated signaling in infected cells (Figure 1-1). Type I IFN expression is regulated, in part, by 
IRFs. IRF3, which is ubiquitously and constitutively expressed in all tissue allowing for rapid 
expression of IFNβ during infection, can be targeted by various viruses (11, 178). HIV-1 and 
ebolavirus (EBOV) are enveloped viruses, retro- and filoviruses respectively, with distinct 
replication cycles, express proteins that meditate direct degradation of IRF3 or block IRF3 
activation by preventing nucleic acid association with cytoplasmic PRRs, respectively (36, 208). 
Additionally, viruses can target the JAK/STAT pathway directly to decrease expression of ISGs 
(154). Moreover, viruses can target ISGs directly (187). Viral genomes are typically very compact, 
encoding proteins with multiple functions. These different strategies exemplify how viruses use a 
limited number of encoded gene products to counter host defenses and ensure replication. Innate 
immunity is the first line of host defense and broad recognition redundancy allows for pathogen 
sensing at all stages of replication from entry to egress.  
 
General Overview of Enveloped Virus Egress 
Egress is the final step of viral replication. For both DNA and RNA enveloped viruses, this 
process involves assembly of genetically encoded structural proteins at host membranes [either 
plasma membrane (PM) or at intracellular structures that are topologically similar, like the Golgi 
apparatus or endoplasmic reticulum (ER)]. These viral proteins subsequently facilitate budding 
and release from the host cell. Viruses express two potential driving forces of membrane 
vesiculation (i.e. formation of vesicles): the viral “core” proteins (e.g. capsid, matrix and/or 
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nucleocapsid) and the viral envelope glycoprotein(s). Viral “core” proteins assemble into higher 
order oligomeric structures prior to or at the site of budding providing the scaffold on which 
nascent virions are generated (Figure 1-3). “Core” proteins themselves are thought to be the 
major drivers of membrane curvature. Mechanistically, this can occur through direct shallow 
penetration into the inner leaflet of the PM, disrupting membrane order to induce curvature (159, 
209); this parallels what is observed with numerous cellular molecules (e.g. BAR domain 
containing proteins, the clathrin adaptor epsin, charged phospholipids) that can sense and/or 
induce similar morphologic changes at membranes (133). Viral glycoproteins, which stud the 
surface of the viral particle and mediate entry into host cells, are targeted to the site of budding 
where some can potentiate membrane coalescence and mediate low levels of vesicle formation 
(39, 139, 145, 161, 237), a property that is thought to enhance viral assembly at sites of budding 
(132). The budding process is tightly orchestrated and requires, in many cases, the aid of cellular 
proteins for completion (38).  
Though viral structural proteins can initiate vesiculation at sites of budding, many 
enveloped viruses encode, within structural proteins, short amino acid motifs known as late-
budding domains (l-domains) that recruit host cell machinery to complete the budding process 
(68). The endosomal sorting complexes required for transport (ESCRT) proteins are commonly 
recruited by viral protein l-domains. Many viruses are dependent on this machinery to complete 
release from the host cell. Under normal cellular conditions, the ESCRT proteins (ESCRT-0, -I, -II 
and -III), perform a topologically similar function during biogenesis of multivesicular bodies 
(MVBs), which involves formation and sorting of vesicles containing ubiquitinated cargo, a 
process conserved from yeast to humans (12, 13, 102). Recruitment of ESCRT proteins is a 
highly conserved mechanism shared by disparate families of enveloped viruses (23). For 
example, HIV-1 and EBOV both recruit the ESCRT-I protein TSG101 via a P(T/S)AP motif found 
on either HIV-1 or EBOV “core” protein, Gag (p6 region) and VP40 matrix, respectively (49, 64, 
138, 233). Additionally, both viruses can also recruit other proteins to perform similar functions; 
for instance, the ESCRT related proteins Alix/AIP1 and/or the HECT ubiquitin ligase NEDD4 via 
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additional l-domain motifs encoded within the “core” proteins (216, 248, 257). Engagement of 
TSG101 leads to the recruitment of ESCRT-III complex members, like CHMP2 and CHMP4, in 
the case of HIV-1 (149). Oligomerization of ESCRT-III complex proteins at the budding neck 
constricts the membrane leading to scission (Figure 1-3A and B). The ATPase Vsp4 mediates 
dissociation and recycling of ESCRT-III components for subsequent rounds of viral replication 
recapitulating what is observed in cellular vesicle biogenesis (14). Other viruses, such as 
influenza and respiratory syncytial virus (RSV), are capable of completing budding independent of 
ESCRT machinery (31, 39, 230). The influenza M2 protein is recruited to sites of budding where it 
inserts into the membrane and in tandem with the M1 protein drive membrane curvature and 
release of viral particles (183).  
Mutations in “core” protein l-domains or perturbation of the ESCRT pathway (genetically 
via RNAi, dominant negative mutants, etc. or chemically via small molecule inhibitors, etc.) can 
block viral budding (57, 76). Mutations typically affect the final scission step of budding. 
Phenotypically, budding-defective viruses have incorporated cellular membranes, but particles 
remain contiguous with the host cell (Figure 1-3C), leading to accumulation of immature virions 
on the cell surface (68). These observations suggest viral budding is a targetable stage of 
replication for therapeutic purposes and therefore an important stage of viral replication to study. 
Expression of “core” proteins alone, like HIV-1 Gag or EBOV VP40, in cell culture systems is 
sufficient to produce virus-like particles (VLPs), which are morphologically indistinguishable from 
infectious virions. This has afforded researchers a tool to study the budding process in isolation, 
using easier and safer VLP-based systems as surrogates of mature virion production for 
numerous clinically relevant viruses that would otherwise require higher biosafety level 
containment. 
With or without host machinery, all enveloped viruses acquire a lipid shell derived from 
host cell membrane upon budding. Many viruses are thought to bud at PM microdomains 
commonly referred to as lipid rafts. Lipid rafts are small liquid-ordered domains suggested to 
range between 10-200nm in size (175). These microdomains are heterogeneous in composition, 
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primarily enriched in cholesterol, but also containing various sphingolipids and lipidated proteins 
typically containing modifications like myristoylation or glycophosphatidylinositol (GPI) anchors. 
Viral membrane lipid composition is thought to be important for steps in the viral replication cycle, 
particularly at steps involving fusion like entry and egress (128, 238). HIV-1 and EBOV 
membranes have been demonstrated to contain lipid raft-enriched molecules like the ganglioside 
GM1 as well as the phospholipid, phosphatidylserine (20, 32, 160). Additionally, numerous 
signaling platforms have been show to localize to lipid rafts (206). Moreover, there is a dense 
actin cytoskeletal network underpinning lipid rafts: likely mediated by the interaction between raft-
localized signaling molecules with actin cytoskeleton regulatory components, which concentrate 
upon receptor clustering within these specific microdomains (42). The actin cytoskeletal network 
plays a role at various stages of viral replication including viral assembly and budding (226). 
Enveloped viruses face the task of budding in an environment dense in cellular proteins.  Many 
viruses prevent bulk host protein incorporation into particles; however, certain host molecules 
present at sites of budding can be preferentially acquired into nascent virions. Acquisition of host 
molecules, in some instances, can be beneficial for viral replication as observed with enhanced 
binding and entry of various enveloped viruses that become enriched with host 
phosphatidylserine (94, 147). As a result of incorporation into virions, host proteins like the 
tetraspanins have been shown to impair infection by restricting membrane fusion. However, it is 
believed HIV-1 can modulate tetraspanin expression on the cell surface during late stages of 
infection to facilitate cell-cell transmission via virological synapses, while reducing production of 
unfavorable syncytia (227). HIV-1 Vpu has been shown to downregulate a number of host 
proteins to regulate HIV-1 egress and replication, including tetraspanins (74, 112), CD4 (250, 
251) the NK coactivation receptor NTB-A (200) and Tetherin (158, 231).  
The interplay between virus and raft-resident molecules at sites of concentrated signaling 
platforms, suggests the cell could sense perturbation of this network during viral replication. ISGs 
restrict various early events of viral replication, though there are a few examples of ISGs that can 
block egress including ISG15, which interferes with ESCRT-viral “core” protein interactions, and 
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viperin, which disrupts raft domains by perturbing lipid composition (155, 163, 164, 244). The 
focus of this dissertation highlights previously understudied properties of lipid raft resident ISG 
involved in blocking viral release, Tetherin, which we now know, not only restricts, but can sense 
viral egress. 
Tetherin: Discovery, Expression, Structure and Topology 
Originally described as HM1.24, Tetherin was identified as a specific surface marker on 
terminally differentiated B cells, suggesting a potential role in B cell development (67, 91). As an 
antigen on immune cells, it was later assigned a cluster of differentiation (CD) nomenclature as 
CD317 (267). The cDNA cloned from the associated gene product recognized by a monoclonal 
antibody against HM1.24 matched a human gene, 540 base pairs in length (180 amino acids), 
located on chromosome 19 annotated as bone marrow stromal cell antigen 2, BST2 (91), 
consisting of 5 exons, 4 of which code for protein (162). The presence of STAT1/3, IRF1/2 and 
IFN-stimulated gene factor 3 (ISGF3) binding sites upstream of the predicted translational start 
site suggested expression could be immune modulated (162). Tetherin has been confirmed as a 
bona fide ISG and is upregulated by IFNs, primarily type I, but also type II and type III (2, 157). 
IFNβ- and γ-induced unphosphorylated STAT1 can stabilize Tetherin mRNA 48h after induction 
allowing for potentially prolonged expression (41). Additionally, expression has also been shown 
to be regulated by alternative mechanisms including a novel, uncharacterized IFN-independent, 
IRF7-dependent pathway (22), the cytokine interleukin 27 (IL-27) (73) and regulated by a 
chromosome proximal, IFN-stimulated long non-coding RNA (lncRNA) (101). Tetherin can be 
highly upregulated in various IFN-responsive cultured cell lines though in primary cells and tissue 
upregulation is thought to be more modest (54). Endogenously expressed Tetherin is present in 
specialized cells across a variety of tissues, as well as cells of the immune system including 
monocytes, macrophages, dendritic cells, NK cells, and B and T cells, (primarily those of Th1 
lineage) (54, 129, 234), and preferentially expressed in certain transformed and invasive cell 
types compared to non-transformed counterparts (33, 194, 239, 240, 242, 243, 252). To date, 
Tetherin orthologues have only been identified in mammals, with the exception of an annotated 
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protein that is Tetherin-like in sequence in Chinese alligator (accession #s: XP_006017475, 
XP006017476), though it has not been tested for functionality. Additionally, in ruminants, gene 
duplication of Tetherin allow for expression of functionally distinct isoforms (9, 152, 225). 
Tetherin is a type II integral membrane glycoprotein of about 30-36kDa in size consisting 
of a short N-terminal cytoplasmic tail, a transmembrane (TM) domain, long coiled-coil ectodomain 
and a C-terminal GPI anchor (Figure 1-4A). It exists as a dimer under physiological conditions 
(91, 109, 162). Dimerization is mediated by disulfide bond formation via three conserved cysteine 
residues localized in the ectodomain. Monomeric forms of Tetherin dimerize in a parallel 
orientation (160). Structurally, Tetherin is unusual, anchored at both the N- and C- termini, by a 
transmembrane domain and GPI anchor respectively (53, 109). To date, the only other 
mammalian protein identified with a similar structure is an alternative form of the prion protein 
(215). Though it is universally accepted that Tetherin is GPI-anchored, at least one line of 
evidence suggests that human Tetherin may express a second transmembrane domain in lieu of 
the processed GPI-anchor signal sequence (5), presumably still allowing to be anchored at both 
termini. The ectodomain, which is extracellular (or lumenal), is primarily a long coiled-coil (~165-
170 Angstroms (Å) relaxed) that can form higher ordered oligomeric species (83, 197, 223, 256). 
Key hydrophobic residues in the ectodomain important for multimerization have been mapped via 
structural data. Tetherin is proposed to also exist as a multimer of anti-parallel dimer of dimers 
(~275Å) interacting via residues near the N-terminus (83, 197, 256). The ectodomain structure 
has been described as “irregular”, with a N-terminal proximal kink observed via small angle x-ray 
scattering approximately about a third of the way into the ectodomain. This feature is believed to 
provide flexibility to the protein (197, 223). Though the cytoplasmic tail and GPI anchor are 
primarily thought to mediate surface Tetherin partitioning, the ectodomain has also been 
suggested to have some contribution to PM distribution (75). The Tetherin ectodomain has two N-
linked glycosylation sites that add ~14-17kDa of complex carbohydrate mass as observed by 
diffuse immunoblot expression profiles. Tight protein resolution can be achieved using PNGase to 
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remove N-linked glycans (Full-length, deglycosylated Tetherin is predicted to be ~19kDa in size; 
confirmed by Western blot analysis after PNGase treatment) (6, 109).  
Tetherin has a short N-terminal cytoplasmic tail, 21 amino acids in length (Figure 1-4A). 
Residues in the tail are important for trafficking and localization. Tetherin localizes primarily to 
detergent-resistant microdomains at the PM, though it is also present in intracellular 
compartments like the trans-Golgi network (TGN) and endosomes (109). Trafficking between 
these compartments is mediated by a tyrosine-based sequence in the cytoplasmic tail that 
resembles overlapping putative recycling motifs (Figure 1-4A). In both rat and human Tetherin, 
the dual-tyrosine motif engages the clathrin-associated adaptor proteins (AP) complexes 1 and 2. 
The AP2 complex mediates Tetherin endocytosis from the PM to endosomes where AP1 
engages and redirects cargo to the TGN where presumably Tetherin is transported back to the 
PM (140). Mutations at both tail tyrosines (Y6, Y8) in the motif are required to fully disrupt 
Tetherin intracellular trafficking, leading to PM stabilization (140, 181). Individual tyrosine 
mutations have no discernable localization defect, though each residue has been proposed to 
interact differently with trafficking machinery by yeast two-hydrid screening (Y6 with AP2 and Y8 
with AP1), suggesting the individual tyrosine residues are perhaps not performing redundant 
trafficking functions (140). 
 
Tetherin Antiviral Function 
Identification of Tetherin as a cellular restriction factor 
The accessory protein Vpu has been described as essential for HIV-1 replication in 
certain refractory cell lines (156, 184). HIV-1 lacking Vpu (delU HIV-1) was shown to accumulate 
at the PM and within intracellular compartments (104). These observations suggested the 
presence of a cell intrinsic factor involved in blocking HIV-1 replication that could be countered by 
Vpu. Additionally, type I IFN stimulation enhanced the budding restriction phenotype (157), further 
evidence that implicated the presence of an uncharacterized immune molecule. The factor in 
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question would remain unknown for almost two decades from the time of the initial observations. 
Neil et al., employing targeted screening of candidate proteins that differed in expression between 
refractory and permissive cell lines, identified an IFN-inducible physiological “tether” that 
prevented release of cell-free delU HIV-1. The gene associated with this phenotype was BST2, 
previously described as HM1.24 and CD317, and thereafter referred to as Tetherin (158) due to 
its “tethering” function of viral particles at the cell surface.  
Breadth of Tetherin restriction and viral antagonists 
In cell culture, Tetherin has been demonstrated to indiscriminately restrict a broad, and 
continually expanding, list of enveloped viral families including alpha- (98, 165), arena- (177, 
185), filo- (99, 100, 157), flavi- (168), rhabdo- (246), alphaherpes- (27, 263), gammaherpes- 
(136), hepadna- (131, 255), orthomyxo- (134), paramyxo- (16), and representative viruses from 
all families of mammalian retroviruses (including endogenous retroviruses (ERVs))  tested to date 
(65, 69, 99, 158). Mouse knockout and knockdown models have suggested Tetherin contributes 
to murine retrovirus restriction in vivo (97, 124, 224). Significant restriction in the murine knockout 
models is believed to require additional IFN stimulation of endogenous Tetherin expression (124). 
Additionally, Tetherin has been demonstrated to enhance cell-mediated immune responses 
during infection (122).  
With few exceptions, most Tetherin-sensitive virus families described to date are believed 
to primarily bud from the PM. There is evidence that Tetherin in macrophages can restrict HIV-1 
in intracellular MVB-like compartments called “virus-containing compartments” (VCCs) (43). 
Hepatitis C virus (HCV), which buds into intracellular membranes, has been suggested to be 
Tetherin-sensitive (46, 169), though work in an inducible system suggests only high Tetherin 
expression levels have any significant effect (258). Recently, Tetherin was shown to also restrict 
hepatitis B virus (HBV), which like HCV buds into intracellular membranes. The HBV work 
suggests interactions in MVBs as Tetherin mutants that have aberrant trafficking and potentially 
accumulate in intracellular compartments have potent function against HBV, but not against a PM 
budding virus like HIV-1 (131). Additionally, herpes simplex 1 and human coronavirus 229E 
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(HCoV-229E), both of which also bud into intracellular membranes, have been shown to be 
Tetherin-sensitive (27, 241). 
Many Tetherin-sensitive viruses encode proteins that counteract tethering function. 
Mechanistically, most virally encoded Tetherin antagonists act by downregulating Tetherin  (i.e. 
removing from the sites of budding). Downregulated Tetherin can either be actively degraded or 
sequestered intracellularly. Both the Kaposi Sarcoma-associated Herpesvirus (KSHV) K5 protein 
and HIV-1 Vpu target Tetherin for degradation. KSHV K5 is an E3 ubiquitin ligase that mediates 
Tetherin polyubiquitination, targeting it to the endolysosomal pathway for degradation (18, 136). 
HIV-1 Vpu recruits the SCF-βTrCP E3 ubiquitin ligase complex via a cytoplasmic di-serine motif 
to mediate ESCRT-dependent endolysosomal degradation of Tetherin (51, 92, 93, 148, 231). Vpu 
binds Tetherin in the TGN to also prevent trafficking back to the PM (7, 52, 79, 195). Intracellular 
sequestration is believed to contribute to maintaining low PM expression. The importance of Vpu 
has been highlighted in humanized mouse models of HIV-1 infection, where Vpu was shown to 
be important in early dissemination of the virus (47, 190). Both HIV-1 Vpu and KSHV K5 are 
thought to interact with Tetherin intracellularly and target lysine residues in the Tetherin 
cytoplasmic tail to mediate downregulation. A serine-threonine-serine region in the tail was shown 
to be required for efficient Vpu targeting of Tetherin (44, 229), though the mechanism is unclear 
(72).  
Unlike HIV-1, most simian immunodeficiency viruses (SIVs) utilize the accessory protein 
negative regulatory factor (Nef) to counter Tetherin. SIV Nef specifically engages simian Tetherin 
through residues in the cytoplasmic tail (see below) and enhances recruitment of the AP-2 
complex, which downregulates surface Tetherin. Contrasting Vpu or K5, Nef activity does not 
result in loss of cellular Tetherin (264) suggesting a sequestration model. Though most SIVs 
utilize Nef to counter Tetherin function, at least one SIV from the tantalus monkey (SIVtan) uses its 
envelope glycoprotein (Env) (70). Inhibition by a retroviral Envs has also been observed in feline 
immunodeficiency virus (FIV), various ERVs and HIV-2 (70, 118, 121, 150). A sequestration 
model has been suggested for primate lentiviral Env-mediated antagonism of Tetherin and at 
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least in HIV-2, occurs by enhancing Tetherin endocytosis via AP-2 (79). HIV-2 Env is thought to 
mediate this interaction via its ectodomain, recognizing an N-terminal region of the Tetherin 
ectodomain (55). Recently, the Chikungunya (CHIKV) accessory protein non-structural protein 1 
(nsP1) (98) and herpes simplex virus 1 (HSV1) M (27) protein have been shown to downregulate 
Tetherin though the mechanisms remain unclear  
Other Tetherin antagonists have been described that utilize less conventional 
mechanisms to counter Tetherin function. Filoviruses also utilize their glycoprotein, GP (100). 
However, unlike SIV and HIV-2 Envs, filovirus GPs are thought to counter Tetherin without 
actively removing it from sites of budding or degrading the protein (100, 126). Recent evidence 
suggests that EBOV GP may facilitate incorporation of Tetherin in budding particles to overcome 
restriction (71). FIV also does not actively downregulate Tetherin and is thought to require 
incorporation into budding particles to function. However, unlike filoviral GPs, which can rescue 
budding of and incorporate into different viral particles in the presence of Tetherin, FIV Env has 
been shown to only rescue release of its cognate FIV “core” protein, p24, suggesting specificity 
between FIV Env and FIV Gag (150).  
Structures/domains important  for viral particle tethering 
Tetherin-restricted particles are distinct from viral particles still associated with host 
membrane due to either mutations in l-domains or mutations in key ESCRT proteins. Particles 
restricted by Tetherin have completed membrane scission and are considered mature (compare 
Figure 1-3 and 4C). This tethering mechanism is direct and proteinaceous in nature as trapped 
particles can be released from the PM by proteinase treatment (158). Tetherin requires anchoring 
at both the N- and C-terminus to function. Rendering Tetherin a single membrane anchor protein 
by either deleting the GPI anchor or TM domain allows surface expression, but prevents particle 
retention (158, 171). These non-functional, single-anchored Tetherin mutants have been 
observed to incorporate into budded virions (171). Restoring anchoring at either terminus by 
engineering chimeric Tetherins partially restores tethering function. An artificial Tetherin (art-
Tetherin) comprised entirely of domains (TM, coiled-coil ectodomain and GPI-anchor) from 
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heterologous proteins has been demonstrated to be sufficient to tether HIV-1 particles, 
suggesting that the cellular restriction function of Tetherin is inherent and primarily mediated by 
structure (171). However, the potency of this art-Tetherin is greatly reduced compared to wt 
Tetherin suggesting some degree of functional specificity to the native structure of the protein. 
While art-Tetherin was expressed at the cell surface, the contributions of the individual 
heterologous domains toward PM localization was not assessed. 
Tetherin incorporation into particles favors GPI-insertion, while the N-terminal 
transmembrane domain anchors the protein to the host cell (232). The cytoplasmic tail of Tetherin 
has been shown to be excluded from raft domains (24), which presents a model where Tetherin 
remains anchored outside the site of budding upon viral particle “tethering” at lipid rafts (Figure 1-
4B and C). Tethered particles are internalized in a Rab5 dependent manner and trafficked to 
endolysosomal compartments where they are degraded. Trafficking to endosomal compartments 
exposes viral protein and nucleic acid to endosomal sensors that may further enhance immune 
responses to infection. Multiple Tetherin dimers are thought to remain present at the assembly 
site. Super-resolution microcopy suggests between 4-7 dimers of Tetherin within single 
microdomains associate with a budding HIV-1 particle, though at least one report using 
quantitative immunoblotting methods suggests this may be an underestimate based on certain 
limitations of the microscopy technique (120, 232). 
The length and post-translational modifications of the ectodomain of Tetherin appear to 
be important for its function. The ectodomain is able to tolerate many triple alanine substitutions, 
though there are specific regions and point mutations that disrupt function, correlating with 
disruption of ectodomain structure (4, 75, 171). Tetherin glycosylation has been shown to be 
dispensable for restriction of certain viruses like Lassa, Marburg and HBV, but not HIV-1 (131, 
171, 185), though surface localization of the double-glycosylation mutant is greatly impaired 
(171). Additionally, Tetherin dimerization appears to be important for tethering HIV-1, but not 
Lassa virus (186). The cytoplasmic tail of Tetherin has been shown to be unnecessary for 
tethering VLPs for various viruses. However, the tail is important in the context of viruses that 
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encode antagonists that bind and/o target the tail with modifications that counter Tetherin-
mediated particle restriction. 
Tetherin-retrovirus co-evolution 
Intrinsic immune factors, including but not limited to TRIM5α, APOBEC3G and SAMHD1, 
have all been demonstrated to potently restrict retroviral replication, limiting cell- and species-
specific tropism (205, 218). This relationship has been well studied in primate lentiviruses, which 
encode proteins that can antagonize the aforementioned cellular restriction factors (217). TRIM5α 
is believed to block cross-species transmission of primate lentiviruses (77), while SAMHD1 
appears to restrict cellular tropism of specific viruses like HIV-1 from infecting cells of myeloid 
lineage, which express inhibitory levels of SAMHD1 endogenously (86, 111). APOBEC3G 
presents a block to HIV-1 in target CD4 T cells, however, HIV-1 encodes the accessory protein, 
viral infectivity factor (Vif), which targets APOBEC for degradation (137, 202). Tetherin has been 
proposed to contribute to limiting primate lentiviral cross-species transmission (192). While 
Tetherin indiscriminately restricts enveloped viruses, including representative members of all 
retroviral families tested to date, primate lentiviruses specifically counteract Tetherin expressed in 
cognate cell types. HIV-1 Vpu specifically antagonizes human Tetherin through unique 
recognition via the TM domain (105, 143, 235). Sequence variations present in the TM domains 
of various non-human primate Tetherins prevents recognition by HIV-1 Vpu. To date, only three 
other SIVs [greater spot nose monkey (SIVgsn), mona monkey (SIVmon) and mustached monkey 
(SIVmus)] have been identified that use Vpu to downregulate their cognate Tetherins through TM 
recognition (192). Vpu also serves to downregulate surface CD4, a function that contributes to 
efficient viral egress. Though all Vpus from SIVs and HIV-1 subgroup (with the exception of group 
N) can efficiently downregulate CD4, only a subset these have been demonstrated to have anti-
Tetherin function suggesting that the ability of certain Vpus to counteract Tetherin was an 
acquired function through species-specific selective pressure (192).  
HIV-1 arose from independent cross-species transmission events of either SIVcpz or SIVgor 
(201). However, both of these viruses, like most other SIVs, use the accessory protein Nef. 
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Tetherin recognition by Nef requires a five amino acid motif within the cytoplasmic domain found 
on non-human primate Tetherins, but has been lost in human Tetherin. Consequently SIV Nef 
does not counteract human Tetherin. Human Tetherin can be engineered to be Nef-sensitive by 
the introduction of this motif (95, 265). Evidence of SIV adaptability to Tetherin has been 
observed in SIV virus lacking the Nef protein (SIV delNef) passaged in vivo. Viral mutants with 
compensatory changes in Env arise that confer anti-Tetherin function (198). This observed 
adaption has demonstrated how lentiviral Env recognition of Tetherin could have evolved in 
various SIVs that were thought to have given rise to the less prevalent HIV-2. SIVcpz is thought to 
have arisen from transmission of SIVs from two different monkey lineages: one that utilized Vpu 
and one that used Nef. Through selection, Nef ultimately become the dominant Tetherin 
antagonist. This is also reflected in the potency of HIV-1 Vpus form the three different 
phylogenetic groups (M, N, O). HIV-1 from group M have both strong anti-Tetherin and anti-CD4 
function, in part, contributing to group M viruses becoming the pandemic strain. Based upon 
these observations Tetherin has been implicated as a major barrier to primate lentivirus 
speciation. Whether additional biological functions of Tetherin are also impacted by adaptation to 
lentivirus infection is an open question and will be further discussed in Chapters 3 and 4. 
Cellular functions of Tetherin 
Tetherin is hypothesized to act as an organizer of lipid rafts, influencing diffusion and 
distribution of proteins to and between microdomain clusters (25). This function is coupled to its 
interaction with the actin cytoskeleton through its interaction with the protein RICH2 (25, 180). 
Interfering with this interaction leads to disruption of apical actin network in polarized cells (180). 
Regulation of monocyte adhesion to Tetherin-expressing endothelial cells has also been 
observed (260). Additionally, the hamster Tetherin orthologue, Golgi-resident GPI-anchored 
protein (GREG) is primarily Golgi-localized and involved in maintaining Golgi-apparatus integrity 
(123). Of note, hamster Tetherin as well all other mammalian Tetherins contain long coiled-coil 
domains that are reminiscent of golgin family proteins involved in regulating vesicular cargo 
movement within the Golgi-apparatus. Though not topologically similar during function, golgin 
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ectodomain homology potentially highlights the importance of Tetherin structure in its ability to 
restrict viral particles (see Structure/Domains Important for Tetherin Viral Particles). 
Recently, Tetherin was suggested to be involved in regulating autophagy and mitophagy by 
sequestering a suppressor protein LRPPRC, preventing it from inhibiting Beclin 1 and Bcl-2 
function (268). 
Other immunological functions of Tetherin 
Apart from being a cellular restriction factor, Tetherin has been shown to have additional 
immune functions. Tetherin has been implicated in dampening type I IFN secretion in both murine 
and human cells. Tetherin-expressing murine IFN-producing cells cross-linked by an immobilized 
Tetherin mAb demonstrated reduced IFNα secretion after TLR stimulation with single-stranded 
DNA (26). In human plasmacytoid dendritic cells (pDCs), Tetherin has been shown to interact 
with the pDC receptor ILT7, leading to dampening of IRF3 dependent IFNα secretion in activated 
pDCs (35). Recently, it was suggested that during particle restriction at the cell surface, Tetherin 
epitopes that mediate interaction with ILT7 are occluded, which would allow pDCs to secrete IFN 
(21). However, in the presence of Vpu, Tetherin molecules that were not downregulated were 
observed to be relocated from budding sites, leading to pDC dysfunction (i.e. blocking IFN 
secretion) (21) Additionally, Tetherin retention of budding particles on the cell surface enhances 
natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) (1, 8). Enhanced 
presentation of HIV-1 specific epitopes on whole virions suggests Tetherin can serve as a link 
between the innate and adaptive responses. Recently, Tetherin has also been suggested to 
restrict long interspersed nucleotide element-1 (LINE-1) retrotransposition (66). Tetherin was 
identified as a potent activator of the transcription factor NF-κB in a screen attempting to identify 
novel and uncharacterized activators (191). NF-κB is important for many cell functions (see 
below). The mechanism, including determinants, by which Tetherin activates NF-κB were 
unknown prior to the start my thesis work. Additionally, it still remains unclear whether described 
binding factors (e.g. ILT7) can affect NF-κB signaling. Additionally, the immune consequences of 
       19 
Tetherin-mediated activation of NF-κB, during or independent of, infection still remain to be 
elucidated.  
Tetherin as an Immune Sensor 
Determinants of Tetherin-mediated activation of NF-κB 
BST2 (aka Tetherin) was identified in a large cDNA screen for novel activators of the NF-
κB and MAPK pathways (141). Based upon this initial observation several groups, including ours 
(see Chapters 2 and 3), have over the past 3 years identified determinants of, and requirements 
for, Tetherin-mediated NF-κB activation (25, 44, 59, 60, 228). Tetherin appears to specifically 
activate NF-κB, but not AP-1 or NF-AT (44, 59, 228). Tetherin-induced NF-κB signaling can be 
dampened by a dominant-negative IKKβ suggesting signaling is activated via the classical 
pathway (44, 59, 228). Tetherin isoforms [long (l-) and short (s-)] highlighted in Chapter 2 have 
different signaling functions. s-Tetherin acts as a dominant-negative regulator of l-Tetherin-
mediated signaling (44). Additional signaling-null Tetherin mutants, including s-Tetherin, have 
been shown to also act as a dominant negative, suggesting dimerization and/or multimerization of 
the cytoplasmic tails may be important (see below). Tetherin-mediated signaling, like its viral 
restriction function, is dependent on specific structural domains, as well as sequence motifs.  
The cytoplasmic tail is critical and encodes several determinants of Tetherin-mediated 
signaling. Loss of the dual-tyrosine motif significantly reduces signaling (44, 59, 228). Individual 
tyrosine mutations have varying effects on signaling. Y6 within the dual-tyrosine motif has been 
demonstrated as being crucial residue in what is believed to be a tyrosine-based signaling motif 
similar to an ITAM (60). Tyrosine-based trafficking motifs (YxxΦ, where Φ=bulky hydrophobic) 
resemble tyrosine-based signaling motifs observed in immunoreceptor tyrosine-based activation 
motifs (ITAMs), which have individual tyrosine based motifs space by a series of non-specific 
amino acids (YxxL/IX(6-8)YxxL/I). ITAMs are phosphorylated at the tyrosine residues, providing a 
docking site for src-homology 2 (SH2) domain containing proteins, which typically are intracellular 
kinases that amplify signaling pathways. Tetherin can be phosphorylated at either or both 
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cytoplasmic tyrosine, Y6 or Y8 (60, 211). However, the Tetherin dual-tyrosine motif does not have 
the proper spacing between tyrosine residues observed in classical ITAMs. hemITAMs, however, 
represent a class of signal activating motifs with single tyrosine residues. This motif has been 
observed on the dimeric immune sensor C-type lectin 2 (CLEC-2) and meditates recruitment of 
Syk kinase. Tetherin dimerization is important for signaling suggesting that Tetherin 
phosphorylation could parallel what is seen with receptors like CLEC-2 (87).  
Triple alanine scanning mutagenesis has been performed on the cytoplasmic tail 
identifying additional sets of amino acids that are required for signaling. Mutations at both an 
arginine and valine residue believed to be under positive selection at positions 10 and 11 (RV) 
abrogate signaling (59). Additionally, a region of basic residues that is proximal to the inner leaflet 
of the PM was identified to be important. The arginine (R19) at the center of the set of triple 
mutants in the basic patch has been identified as a rare polymorphism in humans (R19H). 
Mutation at this site alone abrogates signaling (60, 191). Across all the point mutants tested, 
ability to restrict particles was never compromised suggesting residues are specific for signaling 
function.  
Though the cytoplasmic tail plays an important role in signaling, additional residues and 
domain have also been identified (Figure 1-5). Residues in the transmembrane domain have 
been suggested (see below). The GPI anchor appears to be important, as addition of a premature 
stop codon before the GPI-anchor signal sequence abrogates signaling (59). However, merely 
deleting the C-terminal serine residues that  could potentially act as GPI anchor sites still allows 
Tetherin to signal (228). It remains unclear whether this deletion mutant has actually lost the 
addition of the GPI-anchor. Replacing the GPI anchor with TMs from heterologous proteins, 
including ones that localize to rafts, do not restore signaling to wt Tetherin levels though it is 
suggestive that a second anchor is important (25). Furthermore, the chimeric proteins used in the 
study did not restore wt Tetherin microdomain localization suggesting raft localization plays an 
important role for signaling (25). Additionally, loss of both N-linked glycosylation dampens 
signaling most likely due to mislocalization as this mutant has been previously observed to 
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reduce PM expression (171). Based on the body of literature available, Tetherin-mediated 
signaling is believed to be enhanced by clustering of Tetherin multimers at the PM. Mutations at 
residues that promote multimerization (L70D, L123P) abrogate signaling (59, 228) and do not 
promote enhanced activation during viral egress. Tetherin has been suggested to organize raft 
microdomains (25). Changes in Tetherin structure, through viral particle sensing, presumably 
enhances coalescing of raft microdomain and subsequent migration and recruitment of raft 
resident signaling platforms. 
Tetherin as a novel pattern recognition receptor 
Tetherin restriction of a broad range of enveloped viruses coupled with this previously 
uncharacterized signaling function suggested a role in sensing viral egress. In Tetherin 
expressing cells NF-κB activation, as measured by reporter assay, was enhanced compared to 
Tetherin-null or knockdown cells, using both VLP-based systems and replication competent 
viruses (MLV and delU HIV-1) in stable cell lines. This correlated with enhanced cytokine mRNA 
expression in primary CD4 T cells (59). Tetherin-mediated signaling leads to activation of various 
cytokines including the proinflammatory cytokines IL-6 and CXCL10. When HIV-1 expresses Vpu, 
reduced NF-κB activation is observed. Though a Vpu mutant (A14L) that has lost its ability to 
interact with Tetherin allowed activation of NF-κB (59, 235), it is unclear whether this Vpu mutant 
affects signaling independent of Tetherin as Vpu has been shown to dampen NF-κB by stabilizing 
IκB (28). Additionally, enhanced IFNβ mRNA expression was observed in the presence of 
replication competent virus. Tethered particles are thought to be endocytosed and degraded in 
endolysosomal compartments. The current theory suggests that enhanced IFNβ is the result of 
viral nucleic acid being sensed by an endosomal receptor. Sensing and subsequent signaling is 
dependent on efficient assembly and budding of viral particles. L-domain mutant MLV fails to 
robustly activate NF-κB. Replacing the mutant l-domain with the p6 region of HIV-1 restores 
activation (59). Additionally, blocking endocytosis enhances signaling suggesting virion 
accumulation plays an important role. Clustering of particles leads to aggregation of Tetherin at 
the PM, a model that is also supported by the observation that Ab crosslinking of Tetherin at the 
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PM also enhances signaling (59). Sensing of viral particles correlates with phosphorylation of the 
dual tyrosine motif. Genetic and chemical perturbations suggest activation by the putative 
hemITAM is Src and Syk kinase dependent. The interaction between Tetherin and the actin 
cytoskeleton through RICH2 is crucial as knockdown of RICH2 or disruption of the actin 
polymerization by cytochalasin D reduces the hypothesized Tetherin-mediated Syk activation 
(60).  
Tetherin-mediated signaling as an acquired function in humans during primate speciation 
 Regions in the cytoplasmic tail are thought to have undergone positive selection in 
primates. Signaling by human Tetherin appears to be an acquired function from these 
adaptations. This function, in part, has been suggested to have contributed to the selection of the 
current HIV-1 pandemic strain, M; subtypes of which make up about 90% of the circulating cases 
worldwide (82). Human Tetherin is the only primate Tetherin with signaling function identified to 
date. Tetherins from chimpanzee, gorilla, African green monkey and rhesus macaques do not 
signal, nor does Tetherin from mouse and various felids; a caveat of these findings being that 
signaling was tested in human cells (59). It is unclear whether non-human Tetherin proteins 
signal in the appropriate cognate cell, though NF-κB signaling is fairly well conserved among 
mammals. Recently, two equine Tetherins were demonstrated to activate NF-κB in human cells 
independent of a tyrosine-based motif (259). It is currently unclear whether they activate similarly 
to what has been described for human Tetherin.  
Tetherin antagonism by primate lentiviruses is specific. Important residues that have 
evolved in primates contribute to hTetehrin signaling (Figure 1-5) including the five amino acid 
Nef recognition motif, which impairs chimp Tetherin, the closest related Tetherin to humans. 
Deletion of this Nef recognition sequence allows chimp Tetherin to signal; conversely, 
introduction of this sequence into human Tetherin abrogates signaling (59). The RV region 
described above is under positive selection in primates. The previously described RV tail 
sequence and a two amino acid insertion into the TM only present in human and chimp Tetherin 
are also important. Additionally, the STS region was previously identified to be important for Vpu 
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mediated downregulation of human Tetherin (229). Introduction of the rhesus sequence (PIL), but 
not the chimp sequence which is point mutation S5L, also abrogates signaling (60). This region is 
explored in Chapter 3 of this dissertation. 
Current model for Tetherin-mediated signaling 
To summarize the current model from Galao et al of Tetherin-mediated activation of NF-
κB: Tetherin in a resting cell is believed to interact with RICH2 via its cytoplasmic domain. In this 
model, the actin cytoskeleton, in part mediates sensing of viral particles. Tethered-particles 
clustered at the cell surface enhance phosphorylation of the dual-tyrosine motif in the Tetherin 
cytoplasmic tail by a currently unknown Src kinase. This phosphorylated tyrosine motif is believed 
to act as a hemITAM, which recruits Syk kinase. Syk subsequently activates a series of effectors 
including TRAF2/6 and the TAK1 complex leading to downstream liberation of NF-κB. NF-κB 
induced genes are upregulated (Figure 1-4, (60)), though their role downstream of Tetherin, in 
vivo, is unknown.  
Project Aims 
Tetherin restricts a wide range of clinically relevant enveloped viruses, including HIV-1. A 
large body of work has elucidate how Tetherin directly “tethers” budding viral particles. Functional 
studies have identified the structural features required for viral particle restriction. The Tetherin 
cytoplasmic tail has been shown to be dispensable for tethering particles. However, we know 
aspects of Tetherin biology, like trafficking, are regulated by motifs in the tail. Additionally, virally 
encoded Tetherin antagonists can bind/target sequences in the tail to mediate PM 
downregulation. The human Tetherin cytoplasmic tail has few conserved features across other 
orthologues apart from the previously described dual-tyrosine motif. We sought to identify 
additional features of the cytoplasmic tail that could potentially regulate poorly characterized 
aspects of Tetherin biology. 
In Chapter 2, we describe an internal methionine in the cytoplasmic tail of human 
Tetherin, which is highly conserved in Tetherin orthologues. We hypothesized this codon could 
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act as a downstream in-frame translation initiation site (TIS) based on analysis the Kozak 
sequences flanking the putative upstream start codon and the conserved downstream AUG. 
Because this would yield a truncated isoform lacking, at minimum, the dual-tyrosine motif, we 
hypothesized that the full-length and truncated isoforms could be functionally distinct. There was 
precedent for this hypothesis. Blasius et al. identified Tetherin cDNA from murine cells, which 
only encoded a downstream methionine compared to the full-length annotated sequence (26). 
Upon cloning the full-length form, Blasius et al. observed reduced expression off the upstream 
start codon leading to the hypothesis that the second AUG codon could be the primary start site 
and that the full-length form could have “instability or altered cellular localization” (26). 
Functionally we assessed the ability of the Tetherin isoforms to restrict particle release in the 
presence and absence of the Tetherin antagonist Vpu, and to activate NF-κB. Because NF-κB 
plays an important role in priming early responses to viral infection and Tetherin acts to restrict 
virus, we sought to elucidate this understudied Tetherin function in an attempt to develop a more 
comprehensive picture of Tetherin as an innate immune factor. 
Observations described in Chapter 2, in combination with concurrent work out of the Neil 
and Guatelli groups implicated the dual-tyrosine trafficking motif for Tetherin-mediated signaling. 
We initially hypothesized that differences in signaling between l- and s-Tetherin isoforms would 
help focus on the most important determinants for signaling. It has since been suggested that the 
tyrosine motif can act as a hemITAM (60). However, numerous determinants have been identified 
beyond the dual tyrosine motif within and outside of the cytoplasmic tail (59, 60, 191, 228), which 
suggests a more complex signaling model. Syk has been suggested to interact with Tetherin via 
the hemITAM, however a direct interaction has not been definitively shown. The studies 
described in Chapter 3 were started before a hemITAM was implicated in the current model of 
Tetherin signaling. During the process of identifying determinants of signaling, we discovered that 
our data, from a series of single and multiple point mutations, does not appear to align with the 
current model described above, thereby questioning the mechanism by which Tetherin is 
activating NF-κB. In Chapter 3 we assess the importance of the tyrosine residues within the 
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hypothesized hemITAM, as well as suggest the role of an amino terminal motif that we 
hypothesize regulates Tetherin-mediated signaling.  
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Figure 1-2. Schematic of classical NF-κB signaling through a surface receptor. When the 
cell is rest, NF-κB dimers remains cytoplasmic, sequestered by IκB. Ligand binding by a receptor 
leads to receptor or adaptor phosphorylation at signaling motifs like ITAMs, which recruits SH2 
containing kinases, like Src- or Syk-family kinases. Central to activation of NF-κB via stimuli, like 
TNFα and bacterial LPS. is the TAK1 complex. Phosphorylation leads to activation the IκB kinase 
(IKK) complex, which is comprised of 3 subunits, IKKα, IKKβ and NEMO. The IKK complex 
mediates ubiquitination of IκB and subsequent proteosomal degradation, which frees NF-κB for 
nuclear translocation. NF-κB regulates expression of various genes involved in immunity, 
including proinflammatory cytokines. 
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Figure 1-3. Schematic representation of viral egress. (A) Oligomerized or monomeric viral 
structural protein subunits are targeted to sites of budding. Aggregation of viral proteins at the 
membrane induces curvature, initiating the budding process. Viral “core” proteins recruit ESCRT 
proteins like TST101 (green circle) to facilitate budding and scission. TSG101 recruitment leads 
to ESCRTIII complex (green ring) constricting budding neck, leading to scission (B) Fully budded 
enveloped virion completed scission, acquiring host membrane and specific host molecules in the 
process. (C) l-domain mutant viruses and/or mutations in ESCRT proteins prevents viral budding. 
Particles remain “tethered” to plasma membrane via contiguous host membrane.   
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Figure 1-4. Cartoon representations of Tetherin domains, topology and function. (A) Linear 
cartoons highlighting important functional domains. Top: Graphical depiction of domains and 
modifications with * denoting cysteine residues involved in disulfide bond formation. Two sites of 
N-linked glycosylation are labeled. Bottom: Linear domain model. Residues of the cytoplasmic tail 
of human Tetherin labeled. Dual-tyrosine motif underlined and aligned with putative consensus 
for trafficking motif YxxΦ, where Φ=hydrophobic residue. CT=cytoplasmic tail, 
TM=transmembrane domain (B) Tetherin topology. Top left: Topological cartoon representation of 
a parallel Tetherin dimers (black monomer in front, grey monomer in back) anchored at the 
plasma membrane. Raft domain represented by yellow shapes. Top right: Cartoon depiction of 
Tether tetramers interacting via N-terminal hydrophobic faces on ectodomain Bottom: Looking 
down on cell surface, Tetherin molecules depicted spanning lipid rafts (yellow clusters) as dimers 
and tetramers (C) Tetherin localization at sites of budding allows incorporation of one anchored 
end into particle (preferably the GPI anchor), while other end remains membrane associated with 
host membrane. Tethered particles are subsequently endocytosed and degraded.  
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Figure 1-5. Determinants of Tetherin-mediated signaling. Cartoon model of linear Tetherin 
structure described in Figure 1-4A. Red highlighted sequences on cartoon structure abrogate 
signaling when mutated in human Tetherin *= triple cysteines substitution. Alignment of 
cytoplasmic tail and partial sequence of tail proximal TM sequence expanded. Cytoplasmic tail 
residues highlighted in red are single point mutations identified in Chapter 4 that drastically 
impact signaling. Residues highlighted in blue previously identified as important for signaling in 
combination via triple alanine scanning mutagenesis. Residues in gold when introduced into the 
human Tetherin background, abrogates signaling. Tetherins observed to signal highlighted in 
green.  
 
Human        MASTSYDYCRVPM-----EDGDKRCKLLLGIGI 
Chimpanzee   MASTLYDYCRVPMDDIWKKDGDKRCKLLLGIGI 
Gorilla      MASTLYDYCRVPMDAILKKDGGKRCKLLLGIGI 
AGM          MAPILYDYCKMPMDDICKEDRDKCCKLAV--GI 
Rhesus       MAPILYDYCKMPMDDIWKEDGDKRCKLVI--GI 
Mouse        MAPSFHYLPVPMDEMGGKQGWGSHRQWLGAAIL 
Cat          ---------------MVPGRSLGWQRWLGG--- 
Horse        ----------------MGDHRLLRW-LLLVV-V 
Donkey       ----------------MGDHRLLRW-LLL---- 
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Figure 1-6. A proposed model for Tetherin-mediated NF-κB signaling. When cell is at rest, 
Tetherin associates with actin cytoskeleton via RICH2. Activation through Tetherin clustering by 
sensing assembling/budding viral particle (or Ab crosslinking) leads to actin-dependent 
phosphorylation of cytoplasmic tyrosine motif by an unknown src-kinase. Syk recruitment to this 
hemITAM activates downstream complexes consisting of TRAF2/6, TAK1, and TAB1/2, which 
leads to IKK complex activation. IKK mediates ubiquitination of IκB, liberating NF-κB for nuclear 
translocation where it upregulates genes like IL-6 and CXCL10. Unlike other traditional TAK1 
mediated signaling pathways, Tetherin does not activate AP-1. 
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ABSTRACT 
 
Tetherin (BST-2/CD317/HM1.24) is an IFN induced transmembrane protein that restricts 
release of a broad range of enveloped viruses. Important features required for Tetherin activity 
and regulation reside within the cytoplasmic domain. Here we demonstrate that two isoforms, 
derived by alternative translation initiation from highly conserved methionine residues in the 
cytoplasmic domain, are produced in both cultured human cell lines and primary cells. These two 
isoforms have distinct biological properties. The short isoform (s-Tetherin), which lacks 12 
residues present in the long isoform (l-Tetherin), is significantly more resistant to HIV-1 Vpu-
mediated downregulation and consequently more effectively restricts HIV-1 viral budding in the 
presence of Vpu. s-Tetherin Vpu resistance can be accounted for by the loss of serine-threonine 
and tyrosine motifs present in the long isoform. By contrast, the l-Tetherin isoform was found to 
be an activator of nuclear factor-kappa B (NF-κB) signaling whereas s-Tetherin does not activate 
NF-κB. Activation of NF-κB requires a tyrosine-based motif found within the cytoplasmic tail of the 
longer species and may entail formation of l-Tetherin homodimers since coexpression of s-
Tetherin impairs the ability of the longer isoform to activate NF-κB. These results demonstrate a 
novel mechanism for control of Tetherin antiviral and signaling function and provide insight into 
Tetherin function both in the presence and absence of infection. 
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AUTHOR SUMMARY 
 
Regulation of innate immunity is critical to maintain a balance between control of a 
perceived threat and immunopathology. The interferon induced cellular factor Tetherin has been 
shown to restrict budding of a broad range of enveloped viruses including the human 
immunodeficiency virus. Though Tetherin appears to be a bona fide viral restriction factor, 
additional cellular functions have been observed including an involvement in actin cytoskeleton 
organization in polarized cells, regulating interferon secretion and signaling through nuclear 
factor-kappa B (NF-κB). Our studies present a mechanism by which Tetherin function is regulated 
at the translational level through the production of alternatively translated isoforms. The short 
isoform of Tetherin was observed to be significantly more resistant to HIV-1 Vpu. In contrast, the 
longer isoform can induce NF-κB activity, a function lacking in the short isoform. Critical NF-κB 
signaling residues include a dual tyrosine motif, which is only present in the long isoform. 
Identification of these isoforms helps to illuminate how Tetherin functions, not only as a restriction 
factor, but also as a signaling molecule. These data highlight a previously unappreciated level of 
regulation and furthers our understanding of additional Tetherin functions. 
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INTRODUCTION 
 
Tetherin (BST-2/CD317/HM1.24) is an interferon (IFN) induced, type II transmembrane 
glycoprotein which has been shown to function as an intrinsic antiviral factor that restricts release 
of a broad range of enveloped viruses, including members of the arenavirus (177, 185), filovirus 
(100, 185), gammaherpesvirus (136, 170), paramyxovirus (177), retrovirus (9, 69, 99) and 
rhabdovirus (189, 246) families. Selective pressure from Tetherin on the aforementioned families 
of viruses is evident because many of these Tetherin sensitive viruses encode proteins that 
counter Tetherin function. To date, several virally encoded Tetherin antagonists have been 
identified, a few of which function through different mechanisms. These include HIV-1 Vpu (158, 
231), KSHV K5 (136), SIV Nef (95), HIV-2 and SIV Env (70, 118), and ebolavirus GP (100). 
Tetherin has an unusual topology that has been shown to be critical for function as a 
restriction factor.  Tetherin is a lipid raft resident protein anchored to the cellular membrane by a 
N-terminal transmembrane domain and a C-terminal GPI anchor (109). Localization to sites of 
enveloped virus budding and anchoring at both ends is needed for Tetherin function as a cellular 
restriction factor through a direct “tethering” mechanism which bridges the viral and host 
membranes (171). The N-terminus also includes a cytoplasmic tail, which contains a tyrosine-
based motif that mediates trafficking between lipid rafts at the plasma membrane and intracellular 
compartments, including the trans-Golgi Network (TGN), via adaptor complexes involved in 
clathrin-mediated endocytosis (140, 181).  Additionally, the Tetherin cytoplasmic tail has a serine-
threonine-serine stretch and lysine residues that were identified as targets for HIV-1 Vpu-
mediated tetherin downregulation through the recruitment of cellular ubiquitin ligase complexes 
(51, 148, 229).                                           
  A number of studies have examined the ability of Tetherin to function as a cellular 
restriction factor; however, there is evidence that Tetherin has additional roles that may be 
important both in the presence and absence of viral infection. Tetherin was originally described as 
a marker on differentiated B cells and was suggested to be involved in B cell development (67, 
       36 
91). It is apparent now that Tetherin is constitutively expressed on various other cells of the 
immune system including macrophages, plasmacytoid dendritic cells (pDCs) and T lymphocytes 
(26, 234). Tetherin is also preferentially expressed on the surface of various transformed and 
metastatic cell types (33, 162), though whether Tetherin is actively contributing to the transformed 
state of the cell is unknown. Additionally, Tetherin has been proposed to act as a scaffold protein 
in polarized cells (180) and contribute to monocyte adhesion to endothelial cells (260). Apart from 
directly restricting viral egress, Tetherin has been shown to have immunomodulatory properties. 
Tetherin regulates cytokine secretion in murine (26) and human pDCs. In human pDCs, Tetherin 
acts as a ligand for immunoglobulin-like transcript 7, which results in modulation of Toll-like 
receptor-mediated IFN and proinflammatory cytokine secretion (35).  Additionally, a cDNA screen 
identified BST-2 (aka Tetherin) as one of several uncharacterized cellular factors that could 
activate NF-κB (191). However, this potential role for Tetherin in signaling has not been further 
explored.  
Here we identify a previously undescribed short isoform of human Tetherin generated by 
alternative translation initiation at an in-frame codon 33 nucleotides downstream of the canonical 
translation start site which results in the production of two Tetherin species.  The long (l-) and 
short (s-) Tetherin isoforms are generated in both cultured and primary human cells.  Importantly, 
the two isoforms have distinct biological properties.  s-Tetherin, which lacks 12 residues present 
in the long isoform, is significantly more resistant to HIV-1 Vpu-mediated downregulation and 
consequently more effectively restricts HIV-1 release in the presence of Vpu than l-Tetherin.  In 
contrast, the ebolavirus glycoprotein (GP) effectively counters both Tetherin isoforms.  We also 
find that Tetherin is a significant activator of NF-κB.  However, the Tetherin isoforms have 
dramatically different signaling potential, with NF-κB activation requiring a tyrosine motif found in 
the l-Tetherin isoform but absent in s-Tetherin. These observations provide insight into how the 
expression of alternatively translated Tetherin isoforms regulates multiple cellular functions and 
begins to shed more light on a poorly characterized signaling property. 
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RESULTS 
 
Alternative translation initiation produces two isoforms of Tetherin    
Sequence analysis of the cytoplasmic tail of Tetherin revealed minimal amino acid 
conservation across species. Residues that were highly conserved included two cytoplasmic 
methionine residues and a dual tyrosine motif (Figure 2-1A), previously found to be involved in 
Tetherin trafficking between the plasma membrane and intracellular compartments (140, 181). 
Methionine codons can function as translation start sites when they are flanked by a Kozak 
consensus sequence, which influences ribosomal binding at the site of translation initiation in 
eukaryotic cells.  Analysis of the human tetherin mRNA sequence revealed that the Kozak 
sequences flanking the first AUG  (M1) appears to be a potentially “leaky” signal due to a non-
consensus pyrimidine at the -3 position (Figure 2-1B) (107).  The downstream methionine (M13) 
appears to be a stronger translation start site with compensatory cytosine residues at positions -1 
and -2, which could enhance the strength in the absence of the purine in the -3 position (106).  
Although neither of these methionine residues can be defined as strong Kozak consensus start 
sites, both sequences display conservation at the important +1 through +4 positions. Analysis of 
the mRNA sequences of Tetherin from other species revealed a similar potentially “leaky” Kozak 
signal for the upstream methionine (Figure 2-S1), suggesting that production of multiple isoforms 
may be a conserved Tetherin characteristic. 
To address whether alternatively initiated Tetherin isoforms could be produced, mutations 
that individually abrogated each of the AUG codons were generated in the wt cDNA (Figure 2-
2A). N-linked glycosylation of Tetherin produces a heterogeneous population of proteins that is 
not well resolved by electrophoresis [(6) and Figure 2-S2], complicating unambiguous 
identification of the observed Tetherin bands.  Therefore, to better differentiate the potential 
isoforms that are predicted to differ by 12 residues (~1.5 kDa), lysates from transiently expressing 
cells were treated with Peptide: N-Glycosidase F (PNGase) to remove N-linked glycosylation 
before analysis by Western blot.  Analysis of deglycosylated lysates from HT1080 cells 
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expressing the wt Tetherin cDNA reveals two major bands of between 15-20kDa (Figs. 2-S2 and 
2-2B); the predicted sizes of proteins initiated at the M1 and M13 translation initiation sites is 
approximately 18 and 16.5kDa respectively. Transient expression of the wt tetherin cDNA 
produces more of the larger form compared to the smaller species.  Expression of the M13I 
mutant in HT1080 cells produces a single major product that aligns with the larger protein species 
seen in wt cDNA transfected cells (Figure 2-2B). The M1A mutant, that abolishes the upstream 
potential initiation site, generates a protein that migrates similarly to the smaller species produced 
by wt cDNA. Co-transfection of plasmids expressing the M1 and M13 mutants recapitulates the 
pattern seen with wt Tetherin (Figure 2-2B). Overall, these data demonstrate that transient 
expression of the wt cDNA produces two alternatively initiated species that we refer to as the l-
Tetherin (long) and s-Tetherin (short) isoforms. 
To address whether expression of the s-Tetherin isoform was due to translational 
leakage, an optimized translational initiation sequence was generated by converting the 
sequence at the -3 position of the upstream M1 ATG in the wt Tetherin cDNA from a pyrimidine 
(T) to a purine (A).  Upon introduction into HT1080 cells of a vector with a strong Kozak sequence 
at the M1 AUG, expression of l-Tetherin was greatly enhanced while expression of s-Tetherin 
was almost undetectable (Figure 2-2B).  This mutational analysis, coupled with the data 
presented above, demonstrates that Tetherin utilizes a non-canonical Kozak sequence to 
produce alternatively initiated proteins with different cytoplasmic tails.  
To determine whether both isoforms of Tetherin are endogenously expressed, non-
stimulated and interferon (IFN)-stimulated 293T, HT1080, HeLa, primary human CD4 T-cell 
lysates were analyzed as described above and compared to 293T cells transiently expressing the 
M13I and M1A mutants. As predicted from previous results, no Tetherin was seen upon analysis 
of deglycosylated proteins from unstimulated 293T and HT1080 cells.  Interferon treatment of 
293T and HT1080 cells induces Tetherin expression and upon PNGase treatment, collapses a 
diffuse banding pattern to two bands that migrate similarly to the two isoforms produced by 
transfection of l-Tetherin and s-Tetherin encoding plasmids (Figure 2-2C, 1st panel and Figure 2-
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S3). This demonstrates that IFN stimulation produces both alternatively initiated forms of 
Tetherin.  Analysis of lysates from HeLa cells, which constitutively express relatively high levels of 
Tetherin, revealed the presence of the doublet in the absence of IFN (Figure 2-2C, 2nd panel). 
Both bands appear to be enhanced after IFN stimulation (Figure 2-S3). Similarly to HeLa cells, 
analysis of untreated primary CD4 T-cells revealed two Tetherin species that were enhanced 
upon IFN stimulation (Figure 2-2C, 3rd panel).  In all cell types tested for endogenous expression 
of Tetherin, roughly equal expression of both isoforms was observed after 48 h of IFN stimulation. 
Expression of the M13I and M1A mutants in 293T cells produced the l- and s-isoforms seen 
above in HT1080 cells, however in this case smaller molecular mass species are seen (denoted 
by an asterisk on the 4th panel of Figure 2-2C and throughout the manuscript). These species are 
only observed in transiently expressing 293T, and not in transfected HT1080 or interferon-
induced cells. Though the derivation of these species is unclear, they may represent a precursor 
or proteolyzed product.  Finally, analysis of cells transiently expressing rhesus or murine Tetherin 
cDNA or IFN treated murine J774 cells demonstrated a doublet indicative of production of two 
isoforms (Figure 2-S4A and B) indicating that production of long and short isoforms of Tetherin is 
a highly conserved feature. In contrast, the rhesus cell line FRhK-4 appears to produce only a 
single Tetherin isoform (Figure 2-S4B).  Taken as a whole, the presence of these isoforms in 
numerous cell types, under various conditions and in multiple species is suggestive of important 
biological roles for the newly identified l-and s-Tetherin isoforms.  
 
Tetherin isoforms assemble into homo- and heterodimers      
Tetherin exists as a disulfide-linked dimer that is believed to represent the functional form 
necessary for viral restriction.  Structural studies on the ectodomain suggest that Tetherin dimers 
may also form higher order aggregates, which may be functionally important (83, 197).  To 
address whether the isoforms interact to form heterodimers, lysates from HT1080 cells 
expressing wt, l- or s-Tetherin were separated under non-reducing conditions and analyzed by 
Western blot. Expression of either the l- or s-Tetherin isoform produced single bands of a 
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molecular mass indicative of homodimer formation (Figure 2-S5A).  In comparison, the wt cDNA 
produced a broader expression profile that overlapped with the l- and s-profiles suggesting both 
homo- and heterodimer formation (Figure 2-S5A). To directly assess the interaction of the l- and 
s- isoforms, a C-terminally FLAG-tagged l-Tetherin and N-terminally AU1 tagged s-Tetherin were 
co-expressed and immunoprecipitated using antibodies to the epitope tags (Text 2-S1).  As 
anticipated for efficient heterodimer formation, immunoprecipitation with either tag effectively co-
precipitated the other isoform (Figure 2-S5B).  As discussed below, the ability to form homo- and 
heterodimers may have significant effects upon the biological activities of Tetherin. 
 
Both Tetherin isoforms restrict particle release, but differ in their sensitivities to viral 
antagonists    
The cytoplasmic tail of Tetherin is dispensable for function as a viral restriction factor 
(171). However, residues in the cytoplasmic tail have been shown to confer sensitivity to viral 
antagonists. For example, a serine-threonine-serine sequence, which is unique to l-Tetherin, has 
been found to be important for efficient Vpu antagonism (229). Using a transient HIV-1 virus-like 
particle (VLP) budding assay, the l- and s- isoforms were analyzed for their ability to restrict viral 
release. Both isoforms were effective viral restriction factors and displayed strong inhibition of 
HIV-1 VLP release (Figure 2-3A, top panel).  The antiviral activity of wt Tetherin, which expresses 
both Tetherin isoforms, is antagonized by co-expression of HIV-1 Vpu with VLP release 
correlating with the level of Vpu expression.  In contrast, antiviral activity of the l-Tetherin isoform 
is exquisitely sensitive to Vpu with significant rescue of viral budding seen at the lowest levels of 
Vpu expression analyzed (Figure 2-3A, top panel).  Additionally, a decrease in l-Tetherin protein 
levels was readily observed at higher levels of Vpu expression (Figure 2-3A, third panel).  
Conversely, the s- isoform appears to be resistant to antagonism by Vpu, with very little VLP 
budding rescue observed at the highest levels of Vpu tested (Figure 2-3A, top panel). Moreover, 
turnover of the s- isoform also appears to be resistant to Vpu as there was no obvious decrease 
in s-Tetherin expression even at the highest levels of Vpu (Figure 2-3A, third panel). 
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To determine whether the differential sensitivity to viral antagonists was a common 
property of the Tetherin isoforms, sensitivity to a different viral factor, the ebolavirus glycoprotein, 
GP, was analyzed.  GP is hypothesized to rescue virus budding in Tetherin-expressing cells 
through a non-cytoplasmic tail-associated mechanism (127) and might therefore be predicted to 
interact similarly with both Tetherin isoforms. In contrast to the results with Vpu, within the range 
of GP levels tested, GP-mediated rescue of budding was similar for wt and the two Tetherin 
isoforms (Figure 2-3B, top panel).  Additionally, total cellular Tetherin protein levels appeared 
unchanged for wt Tetherin and each individual isoform even at the highest levels of ebolavirus 
GP co-expression (Figure 2-3B, third panel).  
To determine whether the differential particle release by the isoforms in response to Vpu 
was due to altered Tetherin cell surface levels, flow cytometric analysis of live cells stained for 
Tetherin was performed.  In Vpu expressing cells, surface wt Tetherin expression followed the 
same trend as the total cell Tetherin protein levels (compare Figure 2-3A third panel and Figure 
2-4). Surface expression of l-Tetherin was downregulated by Vpu to a greater extent than the s-
Tetherin isoform, while wt Tetherin appeared to have an intermediate level of downregulation 
(Figure 2-4).  Analysis of lysates from the cells prepared in parallel with those used for flow 
cytometry confirmed the enhanced degradation of l-Tetherin compared to s-Tetherin observed 
above in both the reduced monomers and stable dimers.  Additionally, preferential degradation of 
the l-isoform was seen in lysates of cells expressing wt Tetherin and high levels of Vpu (Figure 2-
4; arrow). In comparison, there is no difference in the effect of ebolavirus GP on surface or total 
levels for the l- and s- isoforms though a decrease in surface staining was observed across all 
Tetherin constructs tested.  The minimal 2-fold decrease in the mean fluorescence intensity of 
Tetherin surface staining observed in ebolavirus GP expressing cells is consistent with steric 
shielding of epitopes previously documented for this glycoprotein (56, 179) and appears similar to 
the slight decrease noted recently by Lopez and colleagues (127). Overall, these observations 
suggest that the Tetherin isoforms can have different sensitivities to viral antagonists, which may 
have important consequences during natural infection. 
       42 
 
Resistance to Vpu antagonism requires mutations in the tyrosine and serine/threonine 
motifs in Tetherin  
To further explore the basis for the relative Vpu resistance of s-Tetherin compared to l-
Tetherin, a series of mutations were engineered into the 12 residue region unique to l-Tetherin 
(Figure 2-5A).  Two motifs within this region have been proposed to play a role in Vpu mediated 
antagonism; a dual tyrosine motif (amino acids 6 and 8, Figure 2-5A) involved in endocytic cycling 
of Tetherin (195) and a stretch of serine and threonine residues (amino acids 3 to 5, Figure 2-5A) 
that can be ubiquitinated (72, 229). Analysis of HIV-1 VLP release from 293T cells transiently 
expressing a tyrosine mutant AxA produced in l-tetherin expressing cDNA shows decreased 
release in response to Vpu as compared to parental l-Tetherin (lane l-AxA, Figure 2-5B). 
However, the observed decreased Vpu antagonism of AxA is not as pronounced as that seen 
with s-Tetherin. Altering the serine/threonine residues also impairs Vpu mediated particle release 
(lane l-STS, top panel Figure 2-5B). However, as with the tyrosine mutations the effect seen is 
intermediate between l- and s-Tetherin. A mutant that combines the tyrosine and serine/threonine 
changes appears to recapitulate the high level of resistance to Vpu antagonism observed with s-
Tetherin (lane l-SY, top panel Figure 2-5B).  Thus it appears that both these regions are involved 
in Vpu mediated antagonism of Tetherin function. 
Although the tyrosine and serine/threonine mutants appear to similarly affect response to 
Vpu antagonism and particle release, the STS mutant Tetherin protein demonstrates resistance 
to Vpu-mediated degradation comparable to that of s-Tetherin (third panel, Figure 2-5). In 
contrast, the AxA mutant protein levels decrease upon Vpu expression comparably to parental l-
Tetherin (third panel, Figure 2-5).  The combined tyrosine and serine/threonine mutant (third 
panel, lane l-SY) is Vpu resistant like s-Tetherin and the STS mutant. Overall, these findings 
support an important role for the STS region in Vpu mediated degradation of Tetherin. 
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The l-Tetherin isoform is an inducer of NF-κB    
Tetherin has been primarily characterized as a cell intrinsic viral restriction factor.  
However, Tetherin has been proposed to have additional activities including a role in induction of 
the proinflammatory response regulator NF-κB (191).  To confirm that Tetherin was able to 
activate NF-κB, a luciferase reporter assay was employed in 293T cells transiently expressing 
Tetherin. Activation of NF-κB by Tetherin displays a bell shaped curve with decreased stimulation 
at high levels of Tetherin expression (Figure 2-S6), suggesting an optimal range of expression for 
signaling.  Expression of wt Tetherin led to NF-κB activation approximately 20-30 fold over control 
cells transfected with the expression vector alone (Figure 2-6A).  Moreover, Tetherin activation of 
NF-κB is specific since there was no effect upon AP1-regulated signaling (Figure 2-6B).  TRAF6, 
an ubiquitin ligase involved in regulating various signal transduction pathways including NF-κB, 
upregulated both NF-κB and AP1.  Supporting the specificity of the observed effect for NF-κB, 
activation by Tetherin was effectively blocked in a dose dependent manner by expression of a 
dominant-negative form of the NF-κB activating kinase IKKβ (DN-IKKβ, Figure 2-6C).   
We next assessed whether the Tetherin isoforms had differential abilities to activate NF-
κB.  Unlike wt Tetherin, the truncated s-Tetherin isoform displayed no NF-κB activation (Figure 2-
6A).  Conversely, compared to wild type, the l-Tetherin isoform was, on average, a more potent 
activator and increased NF-κB activity approximately 40-fold over basal levels.  As was seen for 
wt Tetherin, NF-κB activation by l-Tetherin was sensitive to inhibition by DN-IKKβ (Figure 2-6C).  
These findings demonstrate that sequences within the 12 amino acid region absent in s-Tetherin 
are required for the signaling events downstream of Tetherin that activate NF-κB.  
 
NF-κB activation requires the tyrosine motif and is negatively regulated by s-Tetherin    
As described above, Tetherin can assemble into hetero and homodimers of the l- and s- 
isoforms.  Given the observations that s-Tetherin does not activate NF-κB, l-Tetherin is more 
potent than wt, and wt Tetherin has an intermediate signaling phenotype to that of l- and s-
isoforms, we investigated whether the short isoform could modulate signaling activity of the 
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longer species. To address this question, varying ratios of the two isoforms were assessed for 
their ability to activate NF-κB.  As seen in Figure 2-7, l-Tetherin mediated NF-κB activation is 
strongly diminished by the presence of s-Tetherin. The ability of s-Tetherin to sharply reduce 
signaling at a 1:1 and 1:3 ratio of l- to s-Tetherin expressing plasmids is supportive of a model in 
which homo-oligomers of the longer species are needed to signal.  Overall, this observation 
suggests an inhibitory role for s-Tetherin in regulating NF-κB signaling by l-Tetherin.  
Within the 12 amino acids unique to l-Tetherin are two highly conserved tyrosine residues 
at positions 6 and 8 (Figure 2-1).  To address whether these residues contributed the ability of the 
longer isoform to activate NF-κB, alanine substitution mutations were generated in the context of 
l-Tetherin and tested by transient expression in 293T cells. Compared to the parent l-Tetherin, the 
ability of the tyrosine mutant (AxA) to activate NF-κB was significantly reduced (Figure 2-6A). 
Although impaired, a low but reproducible level of activity was observed for the dual tyrosine 
mutant. These data suggest that the mutated residues form part of an important signaling motif 
within the cytoplasmic tail region needed to activate NF-κB that is present only in the longer 
isoform of Tetherin. 
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DISCUSSION 
 
Here we identify a previously undescribed isoform of human Tetherin generated by 
translation at an in-frame initiation codon 33 nucleotides downstream of the canonical translation 
start site, which results in the loss of a 12-amino-acid N-terminal sequence.  Alternative 
translation initiation in eukaryotes can occur by 3 different mechanisms: internal ribosome entry, 
reinitiation, or leaky ribosome scanning.  Our analysis indicates that the tetherin mRNA contains a 
“leaky” Kozak sequence around the first AUG codon (M1). Based on the scanning model of 
translation, this would allow the ribosome to skip over the first start codon a fraction of the time, 
leading to initiation at the next in frame AUG (M13). Selective disruption of each AUG and 
introduction of a strong Kozak at the upstream AUG confirmed that alternate sites of translation 
initiation accounted for each of the observed products.  Conservation of an upstream leaky Kozak 
and a second cytoplasmic methionine in most mammalian Tetherin sequences, along with our 
analysis of expression from rhesus and murine cDNAs, suggests that multiple isoforms exist in 
other species and indicate an important biologic role(s) for the two isoforms.  
For many messages with alternatively translated isoforms the resultant proteins display 
distinct functionalities (116, 130, 182, 254). This is clearly the case for Tetherin where we 
identified unique biologic properties for the two isoforms.  Although both isoforms exhibit antiviral 
activity, the shorter Tetherin isoform, derived by initiation at M13, is highly resistant to the 
antagonistic effects of HIV-1 Vpu and therefore may play a more important role in restricting virion 
budding in HIV-1 infected cells. Analysis of mutants in the 12 residues unique to l-Tetherin 
suggests that the combined loss of two tyrosine and three serine/threonine residues accounts for 
the Vpu resistance of s-Tetherin. By contrast, l-Tetherin seems to be hypersensitive to Vpu 
antagonism. However, this longer isoform possesses the ability to induce the immune response 
regulatory transcription factor NF-κB while s-Tetherin does not have this capability.  Expression of 
the wt Tetherin cDNA, which produces both protein species yielded phenotypes for Vpu 
sensitivity and NF-κB signaling that were intermediate between those seen upon expression of 
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the individual isoforms. This likely reflects that fact that when the isoforms are co-expressed both 
hetero and homodimers form, and that the unique properties observed (e.g. Vpu resistance and 
NF-κB signaling) require short-short or long-long homodimers respectively.  
In several other systems where alternative translation initiation produces multiple 
isoforms there are observed differences in the ratios of the isoforms in tissues (130, 182) or under 
various physiologic conditions (3) suggesting regulation of alternative initiation.  For example, the 
levels of glucocorticoid receptor (GR) isoforms vary significantly in different tissues, indicating that 
cells can regulate this ratio with important consequences for GR gene regulation (130). Similarly, 
LPS regulates differential expression of alternatively translated forms of the CCAAT/enhancer-
binding trans-activator proteins C/EBPα and C/EBPβ, producing isoforms with unique properties 
(3).  In our experiments, the ratios of l- and s-Tetherin differed in transient expression versus 
endogenous expression. Lysates harvested 48 h post-transient transfection appeared to produce 
more of the longer species. In contrast, 48 h stimulation with IFN produced roughly equal 
amounts of both isoforms. Interestingly, tissue specific expression of ovine Tetherin isoforms has 
been reported (9); however, the mechanism for generation of these isoforms was not 
investigated. Our analysis of human Tetherin did not query a large number of cell types or 
conditions, therefore it will be interesting to more fully address whether there are instances in 
which the ratio of l- and s-Tetherin is regulated. Conversely, the increased sensitivity of l-Tetherin 
to Vpu compared to s-Tetherin suggests that viral antagonists might alter the isoform ratio. 
Because both NF-κB signaling and Vpu sensitivity appear to be affected by the formation of 
homodimers, this suggests a model whereby subtle changes in isoform stoichiometry, either by 
differential expression or susceptibility to viral antagonists of one isoform, could rapidly and 
dramatically affect Tetherin function.  
The importance of the shorter Tetherin isoform with increased antiviral activity or 
resistance to viral antagonists is strongly supported by recent evidence.  While this manuscript 
was in preparation, a polymorphic allele that abrogated expression from the first methionine 
residue, and thus produced only short isoforms, was described in NZW mice.  In these mice, 
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expression of shorter Tetherin isoforms strongly correlated with decreased Friend retrovirus 
replication and pathogenesis (17). Tetherin sequence variants have also been identified in rhesus 
macaques, African green monkeys and mice (144, 261). Interestingly, none of the identified 
macaque polymorphisms account for the single species we observed by Western blot in the 
macaque FRhK-4 cell line. Further analysis of genomic sequence of tetherin from this rhesus cell 
line is required to determine the form being expressed. 
We find that the ability of s-Tetherin to retain budding HIV-1 virions and to resist Vpu 
more effectively than l-Tetherin appears to be due to loss of tyrosine and serine threonine motifs 
found in the cytoplasmic tail of the long isoform.  Mutation in either motif rendered Tetherin 
partially resistant to Vpu. Combining these two sets of mutations recapitulated loss of Vpu 
sensitivity seen for s-Tetherin suggesting these represent important differences between l- and s-
Tetherin. The tyrosine motif in l-Tetherin is a non-canonical trafficking signal (YXYXXV) that 
engages the AP-1 and AP-2 clathrin adaptors (140, 181); mutations within this sequence alter 
cellular trafficking and distribution (78, 92). It has recently been demonstrated that Vpu impairs 
recycling of Tetherin to the cell surface and that this is a key mechanism for antagonizing 
Tetherin function (195). It will be interesting to determine if s-Tetherin effectively recycles in the 
presence of Vpu or if endocytosis from the cell surface is affected. Also, within the region unique 
to l-Tetherin is a serine-threonine-serine stretch that has been shown to be important for Vpu 
mediated Tetherin degradation (229) although more recent studies have questioned this 
conclusion (72, 229).  Our finding that mutations in this motif confer partial resistance to Vpu 
antagonism and also affect Vpu induced degradation support an import role for this region in 
interactions with Vpu. Interestingly, particle retention and Tetherin degradation appear to be 
separable features because the STS mutant appeared to be resistant to Vpu induced degradation 
while the YxY mutant remained sensitive to Vpu degradation, yet both mutations partially impair 
Vpu induced virion release. Our data is consistent with a model in which both decreased protein 
turnover and altered trafficking account for the ability of s-Tetherin to effectively retain virions in 
Vpu-expressing cells. 
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The observation that the long isoform activates NF-κB while the short isoform shows no 
activity suggests that sequences within the 12 residues unique to l-Tetherin mediate signaling.  
Moreover, data demonstrating higher NF-κB induction by expression of the l-Tetherin isoform 
compared to the wt cDNA, coupled with an inhibitory affect of s-Tetherin on NF-κB activation, 
support a model in which homodimers of the longer isoform are responsible for signaling. Though 
Tetherin does not possess canonical tyrosine-based motifs involved in activating signal 
transduction pathways, there is evidence that dimerization of CLEC-2 allows approximation of a 
non-canonical tyrosine-based motif and permits signaling via Syk kinase (87). Furthermore, 
phosphoproteomic analysis has shown that Tetherin tyrosine residues at positions 6 and 8 can be 
phosphorylated (211).  Moreover, mutation of both these tyrosine residues greatly diminished NF-
κB induction, demonstrating that they are critical for this activity. Because the dual tyrosine 
residues have been shown to be important in trafficking it will be crucial to assess whether 
differential localization may also play a role in activating signal transduction. The ability of a 
dominant negative form of the kinase IKKβ to inhibit Tetherin-induced NF-κB activity indicates 
that activation likely involves the canonical pathway, however the mechanism by which Tetherin 
couples to this pathway remains to be elucidated. Similarly to our findings with Tetherin, it has 
recently been found that the cytoplasmic tail domain of HIV-1 envelope activates NF-κB, but not 
AP1 (176). In this case activation occurs via the canonical NF-κB pathway, with HIV-1 envelope 
directly engaging TGF-β-activated kinase 1 (TAK1).  Whether Tetherin utilizes a similar 
mechanism to specifically activate NF-κB remains to be explored. 
It has been demonstrated that Tetherin is a ligand for ILT7 on human dendritic cells and 
that binding initiates signaling via the ILT7–FcεRIγ complex, inhibiting production of interferon and 
proinflammatory cytokines by dendritic cells (35). It will be interesting to investigate if ILT7, or an 
unknown ligand can modulate NF-κB activation by Tetherin. The viral restriction factor TRIM5α 
has recently been shown to function as a unique pattern recognition receptor recognizing the 
hexagonal lattice pattern of entering retroviral capsids to activate NF-κB and MAP kinase 
       49 
pathways (172). In a similar vein, we speculate that Tetherin could recognize the “pattern” caused 
by budding virions to activate NF-κB. 
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MATERIALS AND METHODS 
 
Cell Culture 
 293T, HT1080 and HeLa cells were maintained in high glucose DMEM + 10% Cosmic Calf 
Serum (Hyclone). Primary CD4 T cells (obtained from the University of Pennsylvania Center for 
AIDS Research Immunology Core, ND307) were maintained in RPMI + 10% FBS (Invitrogen). All 
cells were maintained at 37°C with 5% CO2.  
 
Plasmids and Reagents 
Human tetherin cDNA in pCMV-SPORT6 was acquired from Open Biosystems. Tetherin mutants 
were generated using site-directed mutagenesis by PCR.  Primers for site-directed mutagenesis 
were designed using QuikChange Primer Design Program (Agilent Technologies). The HIV-1 
gag-pol encoding construct, psPAX2 was obtained from Addgene (plasmid 12260). HIV-1 vpu 
and ebolavirus GP cloned into pCAGGS were previously described (100, 204). The NF-κB 
reporter plasmid, pBIIX-Luciferase was provided by Dr. Michael May (University of Pennsylvania). 
The TRAF6 coding region was cloned from a cDNA (Open Biosystems) into pKMyc (Addgene 
plasmid 19400) to generate an N-terminally FLAG-tagged version using an XbaI restriction site 
adjacent to the FLAG-tag. The dominant negative FLAG epitope tagged IKKβ (K44M) plasmid 
was obtained from Addgene (plasmid 11104). The AP1 reporter (Biomyx) and MEKK1-delta 
plasmids were obtained from Dr. Sunny Shin (University of Pennsylvania). 
 
Tetherin Protein Expression Analysis  
 HT1080 cells in a 6 well were transiently transfected with Tetherin expression constructs using 
Lipofectamine2000 (Invitrogen) according to manufacturers instructions. For IFN induction 
experiments, HT1080, 293T, HeLa and primary CD4 T cells were incubated +/- 1000U of 
recombinant type I IFN (PBL Interferon Source) for 48 h. Two days post-transfection/IFN 
treatment, cells were washed with PBS and lysed using RIPA buffer (10mM Tris-HCl pH 8.0, 
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5mM EDTA, 140mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% NP40). Lysates were 
passaged through a 25G needle before being cleared by centrifugation at 17,900x g for 15 min at 
4°C. Cleared lysates were treated with either treated or not with PNGase (New England BioLabs) 
for 2 h, then reduced using DTT containing loading buffer. Samples were separated on a 15% 
Criterion gel (BioRad) and transferred to PVDF membrane.  After blocking in 5% milk TBST (Tris-
buffered saline + 0.1% Tween), Western blots were analyzed for Tetherin expression using rabbit 
anti-BST2 sera (Dr. Klaus Strebel, #11721 National Institutes of Health AIDS Research and 
Reference Reagent Program). 
 
VLP Budding Assay 
2.5x105 293T cells seeded on a 24 well plate were co-transfected with the indicated tetherin 
construct (12.5 ng), an HIV-1 Gag-Pol expression vector pSPAX (50 ng) and increasing amounts 
of (25, 50 or 100 ng) of pCAGSS-vpu or pCAGGS ebolavirus GP using Lipofectamine2000.  Cell 
lysates and supernatants were harvested 48 h post-transfection. Cell lysates were harvested in 
Triton X-100 buffer (50mM Tris-HCl pH 8.0, 5mM EDTA, 150mM NaCl, 1% Triton X-100) with 
Complete (Roche) protease inhibitor cocktail. Cell lysates were cleared by centrifugation at 
17,900x g for 3 min at 4°C. Supernatants containing VLPs were cleared are 1700x g for 2 min at 
4°C. VLPs were subsequently purified by pelleting through a 20% sucrose cushion at 40,000 in a 
TLA120.1 rotor (Beckman) for 30 min. VLPs were resuspended in PBS on ice for 3 h. Cleared cell 
lysates and resuspended VLPs were separated on 15% or 4-15% Criterion gels (BioRad) 
respectively before being transferred to PVDF membrane. Membranes were blocked in 5% milk 
in TBST for 40 min prior to incubation with primary antibody. HIV-1 Gag p24 was detected in 
Western blots for both VLPs and cell lysates using a monoclonal anti-p24 antibody (24-3, 
National Institutes of Health AIDS Research and Reference Reagent Program). The GAPDH 
loading control was analyzed using GAPDH antibody (Calbiochem, CB1001). HIV-1 Vpu was 
detected using HIV-1 pNL4-3 Vpu antiserum (969, National Institutes of Health AIDS Research 
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and Reference Reagent Program). Ebolavirus GP was detected using rabbit antiserum against 
the GP1 portion of the protein (125).  
 
Flow Cytometry Analysis of Tetherin Cell Surface Expression 
293T cells (2.5x105) seeded on a 24 well plate were transiently co-transfected with 25 ng Tetherin 
constructs (wt, l-Tetherin, s-Tetherin or l-AxA) and 100 ng HIV-1 vpu or ebolavirus GP. Two days 
post transfection, cells were washed once with 1xPBS while on the plate. Whole cells were 
removed using cold 1xPBS and the cells were split into equal aliquots used for flow cytometry 
and western blot analysis. Cells used for Western blot analysis were pelleted by centrifugation 
then lysed in Triton X-100 buffer. Lysates were cleared and PNGase treated prior to SDS/PAGE 
Western blot analysis as described above. Cells to be used for flow cytometry were resuspended 
in cold FACS buffer (1xPBS, 1%BSA + 0.05% sodium azide) and pelleted at 2150x g. Cells were 
resuspended in FACS buffer + PE conjugated anti-BST2 antibody (Biolegend). After 1 h 
incubation on ice, cells were washed three times with cold FACS buffer and analyzed on a FACS 
Calibur (BD Biosciences Immunocytometry Systems).  Data analysis performed using FlowJo 
9.3.1 (Tree Star).  
 
Luciferase Assay 
293T cells (2.5x105) were seeded on a 24 well plate and the following day were transfected with 
the indicated tetherin constructs (50 ng) and pBIIX-Luciferase reporter (250 ng) using 
Lipofectamine2000.  In experiments where the long and short isoforms were co-expressed the 
total amount of tetherin expression plasmid was kept constant at 50 ng.  At 30 h post-transfection, 
cell lysates were harvested in Triton X-100 lysis buffer. Lysates were transferred to a black flat 
bottom 96-well plate. Luciferase Assay System substrate (Promega E1501) was added to the 
lysates according to manufacturers directions. Samples were analyzed in a Luminoskan Ascent 
microplate luminometer (Thermo Scientific). Statistical analysis was performed using PRISM 
(GraphPad).  
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Supplementary Methods 
 
Coimmunoprecipitation  
293T cells were transfected with l-Tetherin FLAG and/or AU1 s-Tetherin. Cells were lysed in 
RIPA buffer and cleared as described above. Lysates incubated with either anti-FLAG rabbit 
(Sigma) or anti-AU1 rabbit (Bethyl Lab. Inc.) antibodies bound to Protein A Dynabeads 
(Invitrogen) for 4 hours. Lysates washed three times using RIPA buffer. Beads were boiled in 
RIPA+6x SDS/PAGE loading buffer for Western blot analysis. FLAG-tagged l-Tetherin was 
detected using a FLAG-HRP conjugated antibody (Sigma). s-Tetherin was visualized using the 
anti-AU1 rabbit antibody described above. 
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FIGURES 
  
 
Figure 2-1. Alignment of Tetherin sequences and comparison to a consensus Kozak 
translation initiation sequence. (A) Amino acid alignment comparing the amino-terminal 
cytoplasmic region of Tetherin from various mammalian species. Accession numbers- Homo 
sapiens: NP_004326, Pan troglodytes: NP_001177409 XP_552491, Gorilla gorilla: 
ADI58594, Macaca mulatta: ACV96781, Mus musculus: NP_932763 XP_134266, Rattus 
norvegicus: NP_937767 XP_579725, Sus scrofa: NP_001155227 (CL Sequencer; 80% limit). 
Highlighted conserved residues include two cytoplasmic methionine residues, M1 and M13 
(arrows), and a previously characterized dual tyrosine motif (*). (B). Comparison of the nucleotide 
sequences at the M1 and M13 AUGs in human tetherin mRNA to a consensus Kozak translation 
initiation sequence. Important residues at the −3 and +1 to +4 positions are highlighted in bold 
black text. Human Tetherin does not conform to the consensus at the −3 position. l-Tetherin and 
s-Tetherin refer to proteins initiated at M1 or M13 respectively. R = Purine. 
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Figure 2-2. Tetherin exists as two isoforms. (A) Alignment of the Tetherin amino acid (Black 
text) and cDNA (Grey text) sequences compared to strong Kozak sequence, M1A and M13I point 
mutations (highlighted in black). (B) HT1080 cells transiently transfected with Tetherin encoding 
plasmids (WT, Strong Kozak, M1A, M13I or M1A+M13I) were lysed, treated with glycosidase 
(PNGase) to remove carbohydrate modifications and analyzed by Western blot using a polyclonal 
Tetherin antibody. l = long isoform, s = short isoform (C) Tetherin isoform expression in cell 
lysates from IFN stimulated and unstimulated 293T (1st panel), unstimulated HeLa (2nd panel) and 
primary CD4 T (3rd panel) cells. Deglycosylated tetherin profiles are compared to those from 
transiently expressing 293T cells (4th panel). l- and s- indicate the long and short Tetherin 
isoforms. Stable tetherin dimers (d) and an uncharacterized smaller molecular mass species (*) 
often observed under transient transfected conditions are indicated. 
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Figure 2-3. Tetherin isoforms have different sensitivities to viral antagonists. (A and B) 
293T cells were transfected with a constant amount of an HIV-1 Gag-Pol expression vector, a 
constant amount of the indicated Tetherin expression plasmid and increasing amounts of 
plasmids expressing the viral antagonists (A) Vpu or (B) ebolavirus GP. VLPs (Top panels) from 
supernatants were purified and analyzed for HIV-1 Gag p24 release. Cell lysates were probed for 
cellular levels of HIV Gag and Tetherin. As in Figure 2-2C (*) indicates an undefined species 
often seen upon transient Tetherin expression in 293T cells. Titration of viral antagonists was 
assessed using Vpu and GP specific antibodies. GAPDH is used as a lysate loading control. 
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Figure 2-4. Effect of viral antagonists on surface levels of Tetherin. 293T cells were 
transiently co-transfected with the indicated Tetherin plasmids in the presence viral antagonists 
Vpu or ebolavirus GP. Half the cells were analyzed by flow cytometry. Graph represents of the 
mean MFI from multiple experiments (n = 5); error bars = SEM. Surface Tetherin in the absence 
of viral antagonist was set to 100%. Expression of total cellular Tetherin was analyzed by 
Western blot of PNGase treated lysates from cells not used for flow cytometry. Reduced 
monomers, stable dimmers (d) and an unknown species (*) are indicated. Arrow indicates s-
Tetherin isoform seen in wt+Vpu expressing cells. GAPDH used as a loading control. 
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Figure 2-5. Resistance to Vpu antagonism requires mutations in the tyrosine and 
serine/threonine motifs in Tetherin. (A) Amino acid sequences of l-Tetherin mutants that 
disrupt the tyrosine motif (l-AxA), the serine/threonine residues (l-STS) and the combined mutant 
(l-SY). (B) 293T cells were transfected with HIV-1 Gag-Pol and Tetherin expression vectors plus 
increasing amounts of plasmids expressing the viral antagonist Vpu (25 or 100 ng). VLPs (Top 
panels) from supernatants were purified 48 h post transfection and analyzed for HIV-1 Gag p24 
release by Western blot. Cell lysates were probed for cellular levels of HIV-1 Gag and Tetherin. 
As in Figure 2-2C (*) indicates an unknown species often seen upon transient Tetherin 
expression in 293T cells. Titration of Vpu was detected using anti-Vpu antibody. GAPDH is used 
as a lysate loading control.  
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Figure 2-6. Tetherin isoforms differentially activate NF-κB. (A) 293T cells transiently co-
transfected with either a wt, l-Tetherin, s-Tetherin or l-AxA encoding plasmid plus an NF-κB 
responsive firefly luciferase reporter plasmid were lysed and analyzed for luciferase activity 24 h 
post transfection. Myc-TRAF6 used as a positive control for NF-κB activation. NF-κB signaling 
experiments (n = 8 in triplicates) were analyzed by one-way ANOVA. (B) Luciferase assay for AP-
1 activation was assessed as in (A) using an AP1 responsive firefly luciferase plasmid (500 ng) in 
the presence of the same Tetherin encoding plasmids. MEKK1 and myc-TRAF6 were used as 
positive controls for AP1 activation. AP1 signaling experiments (n = 4 in triplicates) were analyzed 
by one-way ANOVA. (C) wt and l-Tetherin were co-transfected with increasing amounts of a 
FLAG epitope tagged dominant negative (DN)-IKKβ and the NF-κB responsive luciferase 
reporter. Myc-TRAF6 was used as a positive control (n = 3 in triplicates). Representative blot 
showing expression of co-transfected constructs as well as a GAPDH loading control. On the 
Western blots, as in Figure 2-2C, (*) indicates unknown species. In the graphs ns = not 
significant; *** p<0.001. 
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Figure 2-7. s-Tetherin modulates l-Tetherin-mediated NF-κB induction. 293T cells were 
transiently transfected with an NF-κB luciferase reporter and varying ratios of l- and s-Tetherin 
expression vectors with the total tetherin expression plasmids amount kept constant. Cells were 
lysed and analyzed for luciferase activity. In parallel, an l:s titration (black bars) was compared to 
l-Tetherin titrated with empty plasmid (white bars). wt Tetherin signaling (grey bar) was assessed 
during each experimental replicate (n = 9 in triplicate). Two-way ANOVA performed to assess 
statistical significance. A representative Western blot for Tetherin is shown for each set of 
titrations. *p<0.05; ***p<0.001, **** p<0.0001. 
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Figure 2-S1. Comparison of Kozak translation initiation sequences of mammalian Tetherin 
messages. Tetherin cDNA sequences from various mammals (Ensembl Gene IDs: CpzBST2 
(Chimp)- ENSPRTRT00000019678, GorBST2 (Gorilla)-ENSGGOT00000015329, RhBST2 
(Rhesus)- ENSMMUT00000008172, MsBST2 (Mouse)- ENSMUST00000051672; NCBI Ref 
Sequence: RtBST2 (Rat)- NM_198134.1) restricted to approximately half the cytoplasmic tail and 
9 bases upstream of the canonical start codon were aligned and are shown with the deduced 
amino acid sequences under the corresponding codons. Matches to important residues in the 
consensus Kozak sequence (−3, and +1 to +4) are denoted in black in each sequence. In all 
cases, the upstream methionine deviates from the consensus at the −3 position. 
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Figure 2-S2. Resolution of heterogeneous Tetherin expression profile by removal of 
carbohydrate modification with PNGase. Lysates from HT1080 cells transiently expressing wt 
Tetherin cDNA were prepared 48 h post transfection. Lysates were analyzed by Western blot 
using a Tetherin antibody. Left panel (no PNGase), right panel (with PNGase).  
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Figure 2-S3. Endogenous expression of Tetherin isoforms. IFN stimulated or unstimulated 
HeLa, HT1080 and 293T cells were analyzed at 48 h post exposure. Cellular lysates were used 
directly or digested with PNGase and analyzed by Western blot. A lighter exposure of PNGase 
treated profile is shown below the main blot. HT1080 cells transiently expressing wt, l-Tetherin, s-
Tetherin, l+s-Tetherin or wt Strong Kozak mutants were harvested, PNGase treated and analyzed 
adjacent to endogenous Tetherin samples. 
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Figure 2-S4. Expression profiles of rhesus and murine Tetherin. (A) 293T cells were 
transfected with murine Tetherin cDNA. Concurrently, murine J774 cells were IFN treated for 48 
h. Lysates were PNGase treated and analyzed by Western blot using an anti-mouse CD317 
antibody (BioLegend, 127101). Shorter exposure of the transfected 293T cells is shown to the 
right. (B) Lysates from 293T cells transiently expressing rhesus Tetherin cDNA were analyzed 
adjacent to lysates of rhesus FRhK-4 cells. The right panel is a lighter exposure of the 293T lane 
from the same blot. While the J774 cells, the murine and rhesus Tetherin cDNAs produce two 
isoforms, only a single species that corresponds to the upper (presumably l-Tetherin) isoform is 
seen in FRhK-4 cells. 
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Figure 2-S5. Isoforms produce homo- and heterodimers. (A) HT1080 cells transiently 
expressing Tetherin mutants form homodimers. HT1080 transfected with either wt, l-, s- or l+s-
Tetherin were lysed in RIPA buffer. Lysates were PNGase treated for 2 h without denaturation. 
Deglycosylated samples were analyzed under non-reducing conditions and probed for Tetherin 
using anti-BST2 rabbit sera. l:l=Long homodimers; s:s=short homodimers. (B) Co-
immunoprecipitation of epitope tagged isoforms. Cartoon of differentially tagged l- and s-Tetherin 
expression vectors with tags adjacent to the GPI anchor additions site or at the amino terminus 
respectively. Epitope tagged Tetherin isoforms were transiently expressed in 293T cells then 
RIPA lysates were precipitated using the indicated antibodies. Precipitates were analyzed by 
SDS/PAGE and Western blot. Lane 1, mock transfected; Lane 2, wt-Tetherin FLAG; Lane 3, l-
Tetherin FLAG; Lane 4, AU1 s- Tetherin; Lane 5, l-Tetherin FLAG+AU1 s- Tetherin. 
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Figure 2-S6. NF-κB induction varies with Tetherin expression level. 293T cells (2×105) were 
transiently transfected with a range of amounts of Tetherin expression plasmid (12.5, 25, 50, 100 
or 200 ng) and a constant amount NF-κB luciferase reporter. Total DNA transfected was kept 
constant by including empty vector. The results consistently show a bell shaped response for NF-
κB activation by Tetherin. From these results 50 ng was chosen as an optimal amount of plasmid 
for the NF-κB activation assays. This graph is a representative experiment done in triplicate, bars 
= SD 
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ABSTRACT 
 
Tetherin is a potent cellular restriction factor that directly inhibits the egress of a broad 
range of enveloped viruses. Recent lines of evidence suggest Tetherin can act as a pattern-
recognition receptor (PRR) that upon sensing viral particle budding can mediate activation of NF-
κB via a non-canonical tyrosine based motif, correlating with enhanced proinflammatory cytokine 
expression. Here we report that a previously described Tetherin mutant can activate NF-κB in a 
tyrosine-independent fashion, via a similar pathway to wt Tetherin. Tyrosine-independent 
activation requires alteration of a serine-threonine-serine (STS) motif near the amino terminus of 
the Tetherin cytoplasmic tail. As previously reported, this mutant, SY Tetherin, displays Vpu 
resistance. We identified minimal sequence in STS that conferred both signaling function and Vpu 
resistance in the dual tyrosine mutant background, as well as additional determinants of Tetherin-
mediated signaling, including single point mutations that affect NF-κB activation. Introduction of 
acidic residues upstream of the dual tyrosine motif abrogates NF-κB activation. Conversely, 
increased hydrophobicity via bulk alanine substitution upstream of amino acid position 13  permits 
signaling. Our panels of mutants provide insight into how the early steps of Tetherin-mediated 
signaling may be controlled. This data suggests that the first 13 amino acids of Tetherin, unique 
to the long isoform, may be regulatory, rather than involved in direct recognition of signaling 
machinery through a proposed hemITAM  as has been previously reported. 
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INTRODUCTION 
 
Timely sensing of and response to viral infection is crucial for maintaining host 
homeostasis and survival. Pattern recognition receptors (PRRs) represent a number of innate 
and intrinsic immune sensors that recognize broad pathogen associated signatures. Specific 
localization of PRRs allows recognition of various virus-derived ligands, like viral proteins and 
nucleic acid, at sites of entry, genome replication and/or egress. Sensing of pathogen-derived 
ligands can lead to activation of various transcription factors including NF-κB, IRFs and AP1, 
which regulate expression of various immune stimulatory cytokines like proinflammatory 
cytokines and interferon (IFN). Cells also express specific intrinsic sensors and can upregulate 
IFN-stimulated genes (ISGs) that directly block viral replication. These factors can be broadly 
acting like viperin and ISG15 (155, 163, 164, 244), disrupting broadly conserved viral replication 
processes or can be  more specific to particular viral families, like TRIM5α, which plays a role 
specifically recognizing capsid upon HIV-1 entry or APOBEC3G which interfere with retroviral 
reverse transcription (137, 193, 202, 219) 
The mammalian intrinsic cellular restriction factor, Tetherin (BST2, CD317, HM1.24) has 
been suggested to also act as a pattern-recognition receptor (PRR), mediating-sensing of viral 
assembly and budding, thus coupling its “tethering” function to its ability to activate the classical 
NF-κB pathway (59, 228). Tetherin can enhance expression of NF-κB dependent proinflammatory 
cytokines, like IL-6 and CXCL10 (59). IFNβ expression is enhanced in the presence of tethered 
replication competent HIV-1 lacking Vpu (59) presumably from sensing of viral nucleic acids from 
degraded endocytosed particles (158). Tetherin activation of NF-κB, in part, is mediated by a 
dual-tyrosine motif (44, 59, 228) previously shown to also regulate Tetherin localization (140, 
181). Though the non-canonical tyrosine based motif has been demonstrated to be crucial for 
signaling, mutational analysis has demonstrated that additional residues in the cytoplasmic tail, 
as well as residues in the transmembrane domain and ectodomain are important (25, 59, 228) 
suggesting complexity to how Tetherin may be signaling. The GPI anchor has been identified as 
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important (60), though there are conflicting reports (25, 228), suggesting that merely having a 
second anchor may be sufficient. Though the cytoplasmic tail is important, it is not sufficient. 
Swapping the human Tetherin cytoplasmic tail on other protein scaffolds, like on rhesus Tetherin, 
which is signaling deficient, does not allow gain-of-function. 
Tetherin is a lipid raft resident protein, which places it at the site of budding for various 
families of enveloped viruses and also proximal to signaling platforms. Like many common 
signaling receptors, Tetherin clustering, either antibody-mediated or by sensing a “ligand”, 
activates signaling. When the cell is at rest, Tetherin is believed to interact with the actin 
cytoskeleton through an actin associating GTPase activator, RICH2 (60). Upon sensing of viral 
particle budding through the actin cytoskeletal network, a putative hemITAM in the Tetherin 
cytoplasmic tail is phosphorylated. This event is thought to mediate recruitment of Syk kinase to 
initiate NF-κB activation. Syk activation subsequently recruits complexes comprised of molecules 
such as TRAF2, TRAF6, TAK1, TAB1/2 (60).  
Here we describe mutations in the cytoplasmic tail of human Tetherin that allows for 
tyrosine-independent activation of NF-κB. Mutational analysis demonstrates that the STS region, 
upstream of the putative hemITAM, can affect NF-κB activation in manner that is sensitive to 
specific substitutions. One mutant, SY, which replaces the STS sequence with alanine residues, 
had previously been shown to be robustly resistant to HIV-1 Vpu both in VLP and replication 
competent infection assays (44, 247). Here we show that the SY mutant can robustly activate NF-
κB despite the fact that both tyrosine residues are mutated. Furthermore, we demonstrate that the 
SY mutant can activate the classical NF-κB pathway and can signal through similar downstream 
effectors suggesting normal Tetherin mediated NF-κB activation. The mutational analysis 
suggests an important role for the amino terminal, in particular the STS region, of Tetherin in 
regulating NF-κB activation. Together, this work provides evidence to suggest that the dual 
tyrosine motif may be an important regulatory motif rather than a hemITAM.  
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RESULTS 
 
Identification of a tyrosine-independent, signaling competent Tetherin 
We previously mapped residues in the Tetherin cytoplasmic tail that when mutated in the 
l-Tetherin background, conferred HIV-1 Vpu resistance. Mutations in the dual-tyrosine motif and 
an upstream serine-threonine-serine (STS) region (mutant SY, Figure 3-1A), were required to 
produce the Vpu-resistant phenotype observed with s-Tetherin via VLP budding assays and more 
recently during replication-competent HIV-1 infection in a T cell line (44, 247). Further 
characterization of the SY mutant, generated in the l-Tetherin background, revealed that 
compared to wt or long isoform (l-Tetherin) it robustly activated NF-κB independent of both 
tyrosine residues via transient reporter assay (Figure 3-1A). This result was unexpected, as the 
dual-tyrosine motif had previously been shown to be important for signaling (44, 59, 228). Thus 
we sought to further assess the contributions of the individual tyrosine residues for NF-κB 
activation..  
Using site-directed mutagenesis, we generated and analyzed a panel of tyrosine mutants 
including single alanine substitutions at positions 6 (Y6A) and 8 (Y8A), as well as the more 
conservative phenylalanine point mutations Y6F and Y8F (Figure 3-1A). In addition we analyzed 
the dual tyrosine mutations in both alanine (AxA) and phenylalanine (FxF) backgrounds. 
Substitution of tyrosine at position 6 with alanine (Y6A) was sufficient to abrogate signaling, while 
alanine substitution at tyrosine 8 (Y8A) had no effect on NF-κB activation. Unlike the alanine 
mutant, both individual phenylalanine mutations, Y6F and Y8F are able to active NF-κB. Signaling 
by FxF is reduced significantly, similar with was previously observed with alanine mutations at 
both tyrosine residues (Figure 3-1A, (44, 59, 228)). As is the case for the SY mutant signaling 
function is restored in the FxF background when changes to STS (STS to AAA) are made in 
combination (mutant SF, Figure 3-1A). Together, these findings suggest an important, novel role 
of the STS sequence in regulating signaling. 
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The mutant panel above was generated in the (l-Tetherin) background with an isoleucine 
substitution at position 13 (M13I). To ensure that tyrosine independent-signaling phenotype was 
not dependent upon this genetic background, we engineered SY in the wt Tetherin context (WT 
SY) and analyzed it for NF-κB activation. As seen in Figure 3-1B, transient expression of WT SY 
activates NF-κB signaling thus confirming the results seen with in the l-Tetherin background. 
Additionally, the level of activation by SY in either the wt or l-Tetherin background was constantly 
higher than that of wt or l-Tetherin. (Figures 3-1A and B). Previous analyses of Tetherin-mediated 
signaling demonstrated specific activation of NF-κB signaling and not AP-1 (44, 59, 228). In 
agreement with this observation, the SY mutant did not activate AP-1, nor did it activate a more 
complex promoter like that of IFNβ (Figure 3-1C), We decided to assess whether SY Tetherin 
consistently a more robust activator of NF-κB compared to l-Tetherin over a range of transfected 
plasmid. SY signaling was generally more robust than l-Tetherin (Figure 3-1D). Taken together, 
we have identified changes in the amino terminal region of Tetherin that specifically activates NF-
κB. in a tyrosine-independent manner. With the data presented above, we raise doubt to the 
importance of the tyrosine residues and their potential to act as a hemITAM in Tetherin. 
 
SY signaling can be regulated by s-Tetherin 
The basic Tetherin functional unit is thought to be a dimer, which multimerizes with other 
dimeric Tetherin species to enhance signaling function. We previously observed that l-Tetherin 
signaling could be downregulated by increasing amounts of s-Tetherin. We tested whether SY 
signaling is dampened similarly by s-Tetherin by transient reporter assay and observed a 
significant dose dependent decrease in signaling compared to decreasing SY plasmid alone 
(Figure 3-2A). In the presence of added l-Tetherin, signaling remains at levels observed with SY 
alone. Since we previously observed that SY activates much more robustly at lower amounts of 
plasmid expression (Figure 3-1D), this suggests that SY is the functionally dominant species 
compared to l-Tetherin. We have observed l-Tetherin to activate NF-κB more robustly than wt 
Tetherin over a range of plasmid expression, an observation that can be explained by the 
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expression of both l- and s-Tetherin off the wt plasmid (Figure 3-2B, (44)). Signaling by WT SY, 
which expresses SY and s-Tetherin off the same plasmid, has reduced signaling compared to SY 
alone confirming the dominant-negative effect observed when s-Tetherin is independently titrated 
in (Figure 3-2B).  
 
Identification of additional residues important for Tetherin-mediated signaling 
Triple alanine scanning has been performed on the Tetherin cytoplasmic tail, identifying 
runs of residues important for signaling (59). The observation that the Y6F mutant retains 
signaling function, we called into question whether the dual tyrosine motif is acting like a bona 
fide hemITAM. To clarify the requirement within the cytoplasmic tail we sought to identify 
additional single point mutations that may regulate Tetherin signaling. We performed single 
alanine scanning on the entire Tetherin cytoplasmic tail using site-directed mutagenesis and 
identified four residues for which alteration to alanine significantly impair NF-κB activation. In 
addition to the requirement for Y6, a significant but less dramatic effect was observed with an 
alanine substitution at the threonine at position 4 (T4) (Figure 3-3A). Additionally, we confirmed 
the findings that R19 is crucial, and to a lesser extent other membrane proximal basic residues 
previously observed by triple alanine scanning (59). The loss/reduction in signaling for the Y6A, 
R19A, and T4A mutants were confirmed by testing a range of plasmid expression compared to 
the l-Tetherin parental background (Figure 3-3B). Additionally, we observed a conservative 
mutation at position 2 (A2V) led to a loss of signal. However, expression of the glycosylated, 
mature forms of the A2V mutant was poor with the exception potentially explaining the loss of 
signaling ability (Figure 3-3C, lower panel). In contrast an acidic substitution at this position (A2E) 
expresses comparably to l-Tetherin, signaling was abrogated. Combined with the finding that 
alteration of the STS region can restore signaling function to tyrosine mutants, this mutational 
analysis has identified an important role for N-terminal residues of the cytoplasmic tail in Tetherin-
mediated NF-κB activation. 
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Tyrosine-independent Tetherin mutant can signal through a similar pathway as wt Tetherin  
To determine if the SY mutant might provide insight as to how the amino terminal region 
of the cytoplasmic tail contributes to regulation of Tetherin-mediated NF-κB activation., we first 
needed to ascertain if  SY behaves like wt Tetherin. As previously observed with wt and l-
Tetherin, NF-κB activation by SY can be blocked with a dominant negative (DN)-IKKβ (Figure 3-
4A). This demonstrates that similar to wt, SY acts through the classical NF-κB pathway Titration 
of wt IKKβ, which activates NF-κB independent of Tetherin, enhanced signaling in a dose 
dependent manner for wt, l- and s-Tetherin. Increasing the level of IKKβ did not increase reporter 
activation with the SY mutant suggesting that robust activation observed might be saturating the 
available IKKβ in complex present in the cell.  
TAK1 has been found to associate with signaling competent Tetherin constructs (59, 
228). We performed coimmunoprecipitation (co-IP) to assess whether TAK1 could interact with l- 
and s-Tetherin isoforms and the SY mutant (Figure 3-4B). Cell lysates containing transiently 
expressed proteins were immunoprecipitated using an anti-Tetherin Ab. As expected, TAK1 was 
found to associate with wt Tetherin. Both l-Tetherin and SY pulled down TAK1 while the 
signaling-deficient s-Tetherin, did not associate with TAK1. The ability of the AxA mutant in the l-
Tetherin background to precipitate TAK1 was highly variable across multiple experiments.  
Tetherin has been suggested to mediate signaling via a hemITAM motif that directly 
recruits Syk kinase (60). We sought to determine whether SY was still Syk dependent. 293T cells 
transiently transfected with Tetherin mutants and NF-κB reporter were treated for 18h with a Src-
family inhibitor, Piceatannol, or a Syk-kinase specific inhibitor, BAY61-3606. Both resulted in a 
dose dependent decrease in SY-mediated signaling (Figure 3-4C) suggesting Src- and Syk-family 
kinases are required for signaling. Taken together, SY appears to utilize similar downstream 
effectors to wt Tetherin for NF-κB signaling function.  
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Ebolavirus glycoprotein antagonizes the SY mutant tethering function 
We previously demonstrated that the ebolavirus glycoprotein (EBOV GP) can counteract 
l- or s-Tetherin equally well to relieve tethering of HIV-1 virus-like particles (VLPs) (44). This 
agrees with the current model of how EBOV GP may be counteracting Tetherin that suggests a 
mechanism of action that is cytoplasmic tail independent (126). In contrast to the Vpu resistance 
observed above, the SY mutant is effectively antagonized with increasing amounts of EBOV GP 
as determined by efficient VLP release (Figure 3-5, VLP panel). Total Tetherin levels remain 
unchanged as previously observed with other Tetherin constructs tested. Additionally, all forms of 
Tetherin tested are incorporated equally well into VP40 VLPs (Figure 3-5, VLP panel), confirming 
a recent observation suggesting that mechanistically EBOV GP may counter Tetherin by allowing 
incorporation into particles (71). Thus SY Tetherin appears to be resistant to Vpu but not EBOV 
GP mediated antagonism. 
 
Minimal changes in STS that confer signaling phenotype in tyrosine mutant Tetherin 
The SY mutant includes alanine mutations in the STS residues upstream of the dual 
tyrosine motif. Triple alanine scanning mutational analysis by the Neil group showed that this 
mutation did not affect signaling in the wt Tetherin background (59), although we observe 
reduced NF-κB activation in the l-Tetherin background (Figure 3-1A). To identify the requirements 
within the STS region that confers a signaling phenotype mutational analysis was performed in 
the AxA background. These studies revealed that the threonine residue at position 4 (T4) is 
critical to confer NF-κB activation in the AxA background. The level of activation is comparable to 
the SY mutant when T4 is changed alone or in combination with the two other residues in the 
motif (S3T4AxA or T4S5AxA) (Figure 3-6A). Alanine mutations in either serine alone, S3 or S5, 
modestly increases NF-κB activation compared to the AxA mutant (Figure 3-6A) but never to the 
level observed with the SY mutant. 
In addition to the observed effects on NF-κB activation, the changes in SY mutant also 
make Tetherin highly resistant to HIV-1 Vpu (44). To determine if the individual or combined 
       76 
mutations in the region also affected Vpu-sensitivity the STS region mutant panel was analyzed in 
a transient budding assay. We observed that rescue of signaling function correlated with 
resistance to increasing amounts of HIV-1 Vpu (Figure 3-6B). Taken together, though the T4 
mutation in the context of l-Tetherin has a modest effect on signaling (Figure 3-3A), it appears to 
play an important role in allowing signaling function in the AxA background. Furthermore, 
mutation in T4 synergizes with AxA to enhance resistance to Vpu. 
 
Assessing the plasticity of STS region to mutation  
Single alanine substitutions in the STS demonstrated that only residue T4 decreased wt 
Tetherin NF-κB activation levels.  To more thoroughly assess the role of this region in signaling 
more disruptive mutations were generated into this region. Substitutions introducing acidic 
residues at S3 and T4 abrogated signaling, while activation levels were diminished by an acidic 
mutation at S5 (Figure 3-7A). A triple acidic mutation at STS (DED) also does not signal and 
cannot compensate for the loss of the dual-tyrosine motif (DEDAxA) (Figure 3-7A). In general, we 
observed that acidic residues upstream of the dual-tyrosine motif disrupt signaling, which may 
explain why the A2E mutant does not signal (Figure 3-3C).  
The STS region appears to have evolved in primates. Chimp and rhesus sequence from 
the homologous region, STL and PIL respectively have been recently demonstrated to have 
differential effects on signaling in the wt Tetherin background (60). We confirmed these findings in 
the l-Tetherin background. The chimp sequence STL (ChSTL) activated NF-κB to a level that as 
similar to the SY mutant and greater than the l-Tetherin parental background.  This is in 
agreement with data showing that the ChSTL substitution appeared to induce greater NF-κB 
activation in the wt background (60). Introduction of rhesus sequence PIL (RhPIL) abrogates 
signaling. When analyzed in combination with the AxA mutation, the chimp S5L mutation can 
rescue signaling, while the rhesus sequence PIL does not (Figure 3-7B), 
The SY mutant carries five alanine substitutions within the amino-terminal 12 residues of 
the cytoplasmic tail – the region unique to signaling competent l-Tetherin. To determine if there 
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are additional specific sequence requirements needed to maintain signaling function, the 
remaining residues in the cytoplasmic tail upstream of position 13 were analyzed by alanine 
substitution mutagenesis. The additional alanine substitutions were placed in the context of the 
SY mutant (Figure 3-7C) and analyzed by transient expression. Sequential alanine substitutions 
throughout the entirety of the region unique to l-Tetherin did not disrupt signaling function (Figure 
3-7C). Indeed a mutant (Ala11) in which residues 2 through 12 are all alanine induces NF-κB 
activation similarly to SY mutant. Although the region unique to l-Tetherin, in particular the STS 
region, is an important determinant for regulating Tetherin-mediated NF-κB activation these 
results suggest a specific sequence dependent interaction with signaling machinery may occur 
elsewhere on Tetherin which raises questions about the nature of the dual-tyrosine motif and 
whether it acts as a hemITAM. 
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DISCUSSION 
In this work, we utilized a series of mutations to highlight a region in the cytoplasmic tail 
of Tetherin that appears to be involved in activation of NF-κB signaling. Specifically, mutations 
identified in a serine-threonine-serine (STS) region near the amino terminus causes Tetherin to 
signal independently of the dual-tyrosine motif. We previously described this mutant, SY, with 
changes in both tyrosines and alanine substitutions at all three residues in the STS region as 
highly resistant to HIV-1 Vpu (44). Here we find that these same changes are associated with 
high levels of NF-κB activation. Similarly to wt Tetherin, the SY mutant is inhibited by co-
expression of the signaling-deficient s-Tetherin. The cellular requirements for SY mutant-
mediated signaling appears to be analogous to what has been described for wt Tetherin, in that 
the classical NF-κB pathway is used and activation is dependent on Syk kinase (44, 59, 60, 228). 
However, the fact that signaling occurs in the absence of tyrosine residues is inconsistent with the 
current hemITAM model for Tetherin-mediated activation ((60), Figure 3-2).   
Further analysis revealed that when coupled with a dual tyrosine substitution at positions 
6 and 8, the threonine at position 4 (T4) within the STS region is critical for Vpu resistance and 
NF-κB activation. The flanking serine residues appeared to modestly contribute additional 
resistance to Vpu-mediated antagonism in the presence of T4A (Figure 6B) although there is little 
effect on virion release and NF-κB activation. The STS region was previously identified, including 
work from our own group, as being important for Vpu-mediated downregulation of Tetherin (44, 
229). It has been suggested the STS region can be ubiquitinated in the presence of Vpu, though 
this observation remains controversial (72, 228). It is unclear to what extent this STS region can 
be post-transnationally modified in the absence of Vpu, if at all. Modifications like phosphorylation 
or acetylation could inhibit signaling function as observed with our acidic substitutions. 
Furthermore, a modification(s) proximal to the dual tyrosine motif could sterically affect tyrosine 
phosphorylation in the wt or l-Tetherin backgrounds as well as potentially disrupt functions like 
such as sorting or protein stability, which could be important for optimal signaling function. 
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The various mutations introduced upstream of the dual-tyrosine motif in the STS region 
suggest some structural specificity associated with signaling function. The STS region, which 
appears to have been under selective pressure in primates, is not tolerant of acidic mutations. By 
contrast, the hemITAM of CLEC-2 is preceded by a similar tri-acidic (DED) sequence that is 
crucial for hemITAM signaling and triple alanine substitution abrogates its function (88). We 
observe the opposite effect, where hydrophobic/nonpolar residues appear to be favored in the 
presence or absence of the dual-tyrosine motif (Figure 3-1A and 3-6). The polyalanine mutations 
are interesting because these substitutions abrogate any potential motif upstream of residue 13 
and suggest that this region serves as a regulatory motif and not a direct protein-docking site. 
Additionally, the propensity for this region of the cytoplasmic tail to form a longer hydrophobic, 
coiled structure also increases. The introduction of a leucine (S5L) from the chimp sequence 
does not abrogate signaling when the tyrosines are present. In fact, this substitution slightly 
increases NF-κB activation in the wt (87) or l-Tetherin background and restores signaling to the 
dual tyrosine mutant. This observation further supports the hypothesis that signaling is favored by 
hydrophobicity in this region [leucine is one of the most hydrophobic amino acids by hydropathy 
scoring (110)]. Introducing rhesus Tetherin sequence (PIL) abrogated signaling possibly due to 
addition of a helix-disrupting proline that might abolish a required structural feature. Supporting 
the theory that signaling may bot require a tyrosine-based motif is the recent observation that 
equine Tetherin activates NF-κB  when expressed transiently in human cells (259). Both equine 
Tetherin proteins have a very short cytoplasmic tail with no tyrosine and no discernable signaling 
motif. Interestingly, both equine Tetherin proteins contain glycines as the second amino acid 
suggesting a potential myristoylation site. It is tempting to speculate that a hydrophobic 
modification of the equine Tetherin amino terminus could behave similarly to hydrophobic 
mutations we have analyzed in human Tetherin to promote NF-κB  activation. 
Single-alanine scanning within the l-Tetherin background reveals that residues Y6 and 
R19 are also critical for Tetherin activation of NF-κB in agreement with previous results (59). We 
identified the alanine residue at position 2 (A2) to also be important for NF-κB signaling. Because 
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the second codon is important for translation initiation (+4 position of the Kozak sequence), we 
designed and generated mutations that would maintain the integrity of the Kozak sequence.  
Although reduced expression of the A2V mutant, possibly due to protein stability, may explain 
why this mutant does not activate NF-κB, the A2E substitution is stable and does not signal. As 
discussed above for the adjacent STS region, the introduction of an acidic substitution upstream 
of the dual-tyrosine motif may not be compatible with Tetherin signaling function. Finally we found 
that the single alanine point mutations at residue 4 (T4A) in the context of the l-Tetherin 
background constantly reduced the level of NF-κB  activation. The importance this residue was 
likely not uncovered in previously reported triple alanine scanning experiments because, as we 
have observed, runs of hydrophobic residues upstream of the dual tyrosine motif have no effect 
on signaling.  
 The Vpu-resistance phenotype of the SY mutant that we first observed using a VLP 
budding assay has since been documented in the context of replication competent HIV-1 (247). 
However, Vpu from different SIVs and different HIV-1 groups, with the exception of M, have been 
shown to be more indiscriminant about downregulating s-Tetherin (247), suggesting that SY could 
be equally sensitive. The dual tyrosine to phenylalanine mutant, SF, which we also show can 
signal, but not to the degree of SY (Figure 3-1A), has also been tested with live HIV-1, and has 
been demonstrated to be Vpu-sensitive (247). This is most likely due to impaired trafficking 
observed in the AxA mutant since bulky phenylalanines can potentially substitute for tyrosines in 
clathrin-mediated trafficking motifs that interact with AP-2 (249). We hypothesize SY is stable on 
the cell surface, as has been demonstrated with dual-tyrosine mutants and suggested for s-
Tetherin which lacks the endocytosis motif entirely. Perhaps surface stability allows for some 
increased degree of clustering, leading to the enhanced signal observed by SY over both wt and 
l-Tetherin (Figure 3-1D). Surface stability may also partially explain resistance to Vpu, which is 
thought to interact with Tetherin in the TGN (52). 
Tetherin is hypothesized to signal via a non-canonical tyrosine based motif, most likely a 
hemITAM motif (60). This motif has been identified in a number of proteins that act as immune 
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receptors.  Unlike traditional ITAMs, which have interspaced phosphotyrosines, hemITAMs 
contain of single phosphotyrosine and interact with signaling kinases trough dimerization. For 
example, CLEC-2 hemITAM dimerization allows binding to Syk via a hemITAM through an 
unconventional SH2-mediated interaction across single phosphotyrosines residues on adjacent 
CLEC-2 molecules (87). Unlike a previously described Y6A mutation, which abrogates signaling, 
we observed that Tetherin mutants with conservative phenylalanine mutations (Y6F, Y8F) 
activate NF-κB . This is stark contrast to other described hemITAM containing proteins where 
phenylalanine substitutions typically abrogate signaling (210, 262). While it is possible that our 
results can be explained by theorizing that Y6 and Y8 function as redundant, overlapping 
hemITAM-like signaling motifs, there is no precedent for this arrangement. Moreover, the ability of 
the SY mutant, which contains no tyrosine residues in the cytoplasmic tail, to interact with TAK1 
by co-IP and signal is a Syk-dependent manner supports a model that does not involve a direct 
hemITAM-mediated interaction on the Tetherin cytoplasmic tail for signaling function. 
Whole cell phophoproteomic analysis demonstrated that Tetherin is phosphorylated at Y8 
and Y6+8 in combination (211) Interestingly no peptide containing only phoshphorylated Y6 was 
identified, yet our analysis and that of Galao et al. suggest that Y6 is an important residue for wt 
Tetherin signaling, it may be specifically dependent on viral particle sensing. The model for 
Tetherin-mediated signaling through a hemITAM motif has been built, in part, around 
immunoprecipitation of Tetherin with anti-phosphotyrosine antibodies (Abs), which correlated with 
signaling function. There are some inconsistencies observed with this model.   The Y8A mutant, 
which retains transient signaling function, was shown to IP with a phosphotyrosine Ab only during 
MLV infection and not during transient expression (60). Additionally, triple alanine scanning 
mutagenesis of regions overlapping Y6 only (TSY or SYD mutated to AAA) all retained signaling 
function (59), paralleling what we have seen with the STS mutation data described above. One 
hypothesis that fits with our data is that Tetherin phosphorylation specifically, rather than 
recruitment of Syk directly, induces or stabilizes a conformational change in the cytoplasmic tail 
important for signaling, and downstream recruitment of Syk kinase by another protein. Tetherin is 
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a lipid raft resident protein and there are numerous examples of proteins that are solely GPI-
anchored that propagate signals into the cell, including receptors involved in immunity. However, 
Tetherin uniquely contains a cytoplasmic tail in addition to the GPI anchor. Our observation that 
cytoplasmic tail mutations at the amino terminal end can affect signaling suggests that region of 
the tail, could act as a regulatory domain.  
One aspect of SY mutant-mediated signaling that needs to be explored is whether viral 
particle budding enhances activation of NF-κB . When the cell is at rest, Tetherin is believed to 
interact with the actin-binding protein RICH2 via its cytoplasmic tail. The current tyrosine-based 
signaling model suggests that upon actin-dependent activation by, for example, viral budding, an 
unknown Src-kinase is thought to phosphorylate the Tetherin cytoplasmic tail, which recruits Syk 
(Figure 3-2). The interaction with RICH2 does not appear to depend upon the dual tyrosine motif 
as this mutant appears to associate with RICH2 comparably to wt Tetherin as measured by co-IP, 
(60). We propose that RICH2 interaction remains intact with SY Tetherin as the association does 
not appear to be tyrosine dependent. If viral particle budding enhances SY signaling, we would 
hypothesize that src kinase-mediated tyrosine phosphorylation would occur on a currently 
unknown signaling protein that may associate with Tetherin via another domain.   
 The ability of src-family and Syk specific inhibitors to impair Tetherin mediated suggests 
the possibility that the compensatory changes bypass Src-mediated phosphorylation of Tetherin. 
SY, and signaling competent variants that do not have tyrosines, could already be primed to 
signal. In this model Syk recruitment would be through an indirect mechanism and not through a 
hemITAM on Tetherin, but rather some other phosphorylated protein. We observe SY Tetherin 
can interact with TAK1. One possibility is that sequence downstream of M13 can bind another 
effector as long as there is scaffolding or regulatory sequence upstream. As previously stated, a 
conformational change in the tail could facilitate this interaction. Alternatively, Syk could bind an 
adaptor that interacts with Tetherin via the GPI anchor. GPI-anchored proteins can propagate 
signals into the cell though they do not span into the cytosol. This occurs through interactions via 
adaptor proteins. GPI anchored proteins cross-linked with mAb are frequently observed to be 
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associated with Ca2+ bursts and tyrosine phosphorylation (84). Interestingly, Tetherin mediated 
signaling has been suggested to involve Ca2+ as it can be dampened with BAPTA treatment 
(228). s-Tetherin which has an intact GPI-anchor does not signal; this again raises the possibility 
that the cytoplasmic tail could primarily play a regulatory function. Interestingly, we, and others, 
have now shown Tetherin and other signaling competent mutants can interact with TAK1 (Figure, 
3-4, (59, 228). The activation of the B cell receptor depends on TAK1 to mediate NF-κB signaling. 
As previously mentioned Ca2+ flux though previously implicated in ER stress (228) could be the 
result of PLCγ activation via Tetherin leading to NF-κB activation. Future experiments will begin to 
address whether other additional domains mediate interactions that are necessary for Tetherin 
signaling function.  
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MATERIALS AND METHODS 
 
Cell Culture 
 293T cells were maintained in DMEM + 10% Fetal Bovine Serum (Hyclone) at 37°C with 5% 
CO2.  
 
Plasmids and Reagents 
Human tetherin cDNA in pCMV-SPORT6 was acquired from Open Biosystems. All Tetherin 
mutants tested were generated in the l-Tetherin (M13I) background using Change-IT site-directed 
mutagenesis by PCR.  Primers for site-directed mutagenesis were designed using QuikChange 
Primer Design Program (Agilent Technologies). The HIV-1 gag-pol encoding construct, psPAX2 
was obtained from Addgene (plasmid 12260). The pCAGGS ebolavirus FLAG-VP40 plasmid 
used is previously described (100). HIV-1 Vpu and ebolavirus GP cloned into pCAGGS were 
previously described (100, 204). The NF-κB reporter plasmid, pBIIX-Luciferase was provided by 
Dr. Michael May (University of Pennsylvania). The TAK1 constructs were obtained from Open 
Biosystems and cloned into pCMV-SPORT6. The wt and dominant negative (K44M) FLAG 
epitope tagged IKKβ plasmid was obtained from Addgene (plasmid 11104). The AP1 reporter 
(Biomyx) and MEKK1-delta plasmids were obtained from Dr. Sunny Shin (University of 
Pennsylvania). The Sendai virus stock and IFNβ reporter were provided by Dr. Carolina Lopez . 
Transfections were performed using 2.5ul of a 1ug/mL working stock of polyetheylenimine (PEI) 
per 1ug DNA.  
 
VLP Budding Assay 
2.5x105 293T cells seeded on a 24 well plate were transfected with PEI at the described working 
concentration listed above. Indicated tetherin construct (50 ng) was co-transfected with either:  
Gag-Pol expression vector pSPAX (200ng) and increasing amounts of (50 or 200 ng) of 
pCAGSS-vpu for HIV-1 VLP assays or pCAGGS FLAG-VP40 (100ng) and increasing amounts of 
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(50 or 200 ng) pCAGGS ebolavirus GP for EBOV VLP assay. Cell lysates and supernatants were 
harvested 48 h post-transfection. Cell lysates were harvested in Triton X-100 buffer (50mM Trs-
HCl pH 8.0, 5mM EDTA, 150mM NaCl, 1% Triton X-100) with Complete (Roche) protease 
inhibitor cocktail. Cell lysates were cleared by centrifugation at 17,900x g for 3 min at 4°C. 
Supernatants containing VLPs were cleared are 1700x g for 2 min at 4°C. VLPs were 
subsequently purified by pelleting through a 20% sucrose cushion at 40,000 in a TLA120.1 rotor 
(Beckman) for 30 min. VLPs were resuspended in PBS on ice for 3 h. Cleared cell lysates and 
resuspended VLPs were separated on 15% or 4-15% Criterion gels (BioRad) respectively before 
being transferred to PVDF membrane. Membranes were blocked in 5% milk in TBST for 40 min 
prior to incubation with primary antibody. HIV-1 Gag p24 was detected in Western blots for both 
VLPs and cell lysates using a monoclonal anti-p24 antibody (24-3, National Institutes of Health 
AIDS Research and Reference Reagent Program). The loading control used across experiments 
was αtubulin, which was analyzed using αtubulin mAb (12G10). HIV-1 Vpu was detected using 
HIV-1 pNL4-3 Vpu antiserum (969, National Institutes of Health AIDS Research and Reference 
Reagent Program). Ebolavirus GP was detected using rabbit antiserum against the GP1 portion 
of the protein (125). Tetherin expression was assessed using rabbit anti-BST2 sera (Dr. Klaus 
Strebel, #11721 National Institutes of Health AIDS Research and Reference Reagent Program). 
 
Luciferase Assay 
For single concentration assays: 293T cells (2.5x105) were seeded on a 24 well plate and the 
following day were transfected with the indicated tetherin constructs (50 ng) and pBIIX-Luciferase 
reporter (200 ng) using PEI.  Total DNA was kept constant using empty pCMV-SPORT6 vector.  
At 30 h post-transfection, cell lysates were harvested in Triton X-100 lysis buffer. Lysates were 
transferred to a black flat bottom 96-well plate. Luciferase Assay System substrate (Promega 
E1501) was added to the lysates according to manufacturers directions. Samples were analyzed 
in a Luminoskan Ascent microplate luminometer (Thermo Scientific). Statistical analysis was 
performed using PRISM (GraphPad).  
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Co-immunoprecipitation  
1.4x106 cells were seeded on 6 well plate. Following day (~20h), PEI transfection performed on 
cells using 500ng of the indicated Tetherin constructs per well (wt, l-, s-, AxA, SY) + 500ng 
pCMV-SPORT6 TAK1. Control well with TAK1 and wt Tetherin alone done in parallel, with DNA 
normalized using empty pCMV-SPORT6. 18h post transfection, cells were lysed on ice  for 20min 
in TritonX-100 buffer in the presence of freshly added Complete (Roche) protease inhibitor 
cocktail and 1mM sodium orthovanadate (NEB).  Lysates were cleared for 10min at 4°C. Aliquot 
of lysate set aside for input. Remaining lysate incubated with 1.5µg anti-Tetherin Ab (RS39E). 
Abs and lysate incubated at 4°C while rocking for 2h after which washed Protein G Dynabeads 
(Invitrogen) were added for an additional 1h. After incubation, lysates/bead/Ab complex pulled 
down over chilled magnet and washed gently 4x using TritonX-100 buffer removing from magnet 
each time. Protein immunoprecipitated on beads were treated with PNGase via manufacturers 
instructions then boiled in 1x SDS/PAGE loading buffer for Western blot analysis. Loading control 
for inputs was determined using αtubulin (12G10) Ab. TAK1 blotted for using TAK1 (D94D7) 
specific Ab (CST, #5206). Tetherin blotted for using anti-BST2 sera described above.
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FIGURES 
Figure 3-1. Identification of a signaling-competent, tyrosine-independent Tetherin. 293T 
cells were cotransfected with 50ng of various Tetherin constructs and 200ng of firefly luciferase 
reporter. Cells were harvested 24h post transfection for luciferase readout  (A) Tetherin cartoon 
with alignment of mutants generated in l-Tetherin background tested in panel assessing the 
signaling ability of various tyrosine mutants. Tetherin constructs were cotransfected with pBIIX-
Luc for NF-κB activation. Values normalized to l-Tetherin background set to 1 (grey dotted line). 
Graphs represent experiments done in triplicate (n=4); error bars= SEM *p<0.05(B) Alignment of 
mutants generated in the wt Tetherin background. Tetherin constructs were cotransfected with 
pBIIX-Luc for NF-κB activation. Graph normalized to wt Tetherin background set to 1 (grey dotted 
line). Graph represents experiments done in triplicate (n=3); error bars= SEM ** p<0.01, 
****p<0.0001 (C) l-Tetherin and SY cotransfected with either AP1 reporter (left) or IFNβ reporter 
(right). Reporter activation controlled for using MEKK1 for AP1 and incubation with Sendai virus 
for IFNβ. Graphs are representative of multiple experiments done in triplicate; error bars=SD. 
Representative lysates ran under denaturing conditions blotted for Tetherin and GAPDH as 
loading control. (D) Increasing ramp of Tetherin plasmid (12.5ng, 25ng, 50ng, 100ng and 200ng) 
were cotransfected with pBIIX-Luc for NF-κB activation. Graph is a representative of multiple 
experiments done in triplicate.    
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Figure 3-2. SY signaling can be regulated by s-Tetherin. 293T cells were transiently 
transfected with 50ng of total Tetherin plasmid(s) and 200ng of firefly luciferase reporter. Cells 
were harvested 24h post transfection for luciferase readout. Graphs from (A) and (B) come from 
the sets of experiments. (A) 293T cells were transiently transfected with SY Tetherin and titrated 
with empty vector (black bars), l-Tetherin (grey bars) or s-Tetherin (white bars). Total amount of 
plasmid transfected was kept constant for titrations. Graph represents multiple experiments done 
in triplicate (n=5); error bars= SEM. T-test performed between SY:empty and SY:s- conditions 
*=p<0.01. Lysates from representative experiment, PNGase treated and blotted for Tetherin. 
Loading controlled for by αtubulin staining. (B) Graphs represent comparison signal of 50ng of 
either wt Tetherin (top) or wt SY (bottom) compared to different ratios (50ng total) 
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Figure 3-3. Identification of additional point mutations important for Tetherin-mediated 
signaling. 293T cells were cotransfected and lysates were harvested 24h post transfection (A) 
Tetherin cartoon with alignment of alanine mutants generated in l-Tetherin background tested in 
panel for effects on NF-κB signaling. M13I mutation highlighted in grey. Red letters indicate single 
point mutations that completely abrogate signaling. Arrows denotes residues that have a modest 
effect on signaling. Tetherin constructs cotransfected with pBIIX-Luc. Values normalized to l-
Tetherin background set to 1 (grey dotted line). Graph represents experiments done in triplicate 
multiple times (n=4); error bars= SEM (B) Increasing ramp of Tetherin plasmids (12.5ng, 25ng, 
50ng, 100ng and 200ng) were cotransfected with pBIIX-Luc for NF-κB activation. Graph is a 
representative of multiple experiments done in triplicate. (C) Two different A2 mutations tested in 
ramp with 200ng pBIIX-Luc reporter for NF-κB signaling, compared to 200ng of l-Tetherin 
background. Denatured lysates from a representative experiment probed for Tetherin expression 
compared to l-Tetherin background. 
  
l-
M
1A A
2V
S3
A
T4
A
S5
A
Y6
A
D
7A Y8
A
C
9A
R
10
A
V1
1A
P1
2A
M
13
A
E1
4A
D
15
A
G
16
A
D
17
A
K
18
A
R
19
A
C
20
A
K
21
A
0
1
2
3
Tetherin Construct
Fo
ld
 A
bo
ve
 B
as
al
 N
F-
κB
 
(V
al
ue
s 
N
or
m
al
iz
ed
 to
 l-
 =
 1
) MASTSYDYCRVPIEDGDKRCK 
A 
B 
C 
A2V A2E 
l- 
25kDa 
20kDa 
15kDa 
Tetherin 
20
0 50 10
0
20
0 50 10
0
20
0
0
1
2
Amount Tetherin Plasmid (ng)
Fo
ld
 A
bo
ve
 B
as
al
 N
F-
κB
 
(V
al
ue
s 
N
or
m
al
iz
ed
 to
 l-
 =
 1
)
l-
A2V
A2E
0 20 40 60 80 100
0
50
100
150
Amount Tetherin Plasmid (ng)
Fo
ld
 A
bo
ve
 B
as
al
 N
F-
κB
 
l-
SY
       91 
Figure 3-4. Tyrosine-independent Tetherin mutant can signals through a similar pathway 
as wt Tetherin. 293T cells were transiently cotransfected and lysates were harvested following 
day (A) wt, l-, s- and SY Tetherin constructs were cotransfected alone, or with increasing 
amounts (25ng and 100ng) of either wt FLAG-IKKβ or DN FLAG-IKKβ (K44M) plus 200ng of 
pBIIX-Luc reporter for NF-κB activation. Graphs represent multiple experiments done in triplicate 
(n=3); error bars= SEM. Lysate from a representative experiment blotted for IKKβ and Tetherin 
(B) 293T cells transfected with equal amount of Tetherin or TAK1 expressing plasmid. Lysates 
harvested 20h post transfection. Small input fraction saved for expression control. Remaining 
lysate coimmunoprecipitated using Tetherin monoclonal antibody. Protein was PNGase treated 
directly on bead after last wash in protocol. Lysates blotted for Tetherin and TAK1. Inputs 
included αtubulin. (C) 6h post transfection with Tetherin construct (wt, l-, s- or SY) with pBIIX-Luc 
reporter for NF-κB activation, media was changed with increasing amounts of either Piceatannol 
(top) or BAY61-3606 (bottom). Cells treated in drug for 18h before harvest. Graphs represent 
multiple experiments done in triplicate (Pic, n=3; BAY61, n=4).  
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Figure 3-5. Ebolavirus glycoprotein antagonizes the SY mutant tethering function. 
Ebolavirus (EBOV) VLP budding assay in 293T cells. Cells were transiently transfected with 
100ng Tetherin construct (wt, l-, s-, SY), 100ng FLAG-eVP40 and increasing amounts of EBOV 
GP (eGP) (50ng and 200ng). Supernatants were purified to isolate VLPs and cell lysates 
generated for total protein assessment 48h post transfection. VLPs probed for FLAG stripped and 
reprobed for incorporated Tetherin. Cell lysates probed for eGP using a GP specific Ab, FLAG 
and Tetherin. αtubulin used as protein leading control. 
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Figure 3-7. Assessing the plasticity of STS region to mutation. 293T cells were cotransfected 
with 50ng of various Tetherin constructs and 200ng of firefly NF-κB luciferase reporter, pBIIX-Luc. 
Cells were harvested 24h post transfection for luciferase assay. Tetherin cartoon with alignment 
of mutants generated in l-Tetherin background for each panel tested. Values for all graphs 
normalized to internal l-Tetherin background, which is set to 1 (grey dotted line). (A) Acidic 
mutations. Graph represents multiple experiments done in triplicate (n=3); error bars= SEM (B) 
Hominid sequence swaps with hominid cytoplasmic tail alignment below. Graph represents 
multiple experiments done in triplicate (n=4); error bars= SEM *p<0.05 , **p<0.01 (C) Polyalanine 
mutations. Graph represents multiple experiments done in triplicate (n=3); error bars= SEM 
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CHAPTER 4: GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
Summary and perspectives on Tetherin isoforms 
In this dissertation, we have elucidated novel biology for the cellular restriction factor, 
Tetherin. A large body of research has focused on various facets of how Tetherin restricts 
enveloped virus budding, which includes characterization of structural determinants necessary for 
tethering function, identification of viruses that are Tetherin-sensitive and whether these viruses 
encode a Tetherin antagonist, and determining, mechanistically, how virally encoded antagonists 
counter Tetherin-mediated restriction (See Chapter 1). Tetherin has a short cytoplasmic tail, 
which is dispensable for tethering viral particles, though it can be targeted directly by virally 
encoded antagonists for downregulation to allow efficient viral replication. Aside from a tyrosine-
based endocytic motif, a second cytoplasmic methionine, downstream of the putative start codon, 
is highly conserved among Tetherin orthologues.  
In Chapter 2 we determined that the nucleotide sequences surrounding the downstream 
cytoplasmic methionine codon was in an appropriate genetic context to act as a potential 
alternative start codon. Additionally, we observed that the putative primary start codon was in the 
context of a suboptimal Kozak sequence (Figure 2-1B) suggesting potential ribosomal leakage. 
The pre-initiation ribosomal complex composed of the 40S ribosome and Met-tRNA scan AUG 
codons in this Kozak context and rather than initiate translation, skip over the potential start site a 
fraction of the time (108). wt Tetherin cDNA with the endogenous Kozak sequence produces two 
species: l-Tetherin, which is considered full-length expressing off the upstream open reading 
frame (uORF), and s-Tetherin, which expresses off an in-frame ORF located 12 codons 
downstream of the putative start site. Resolution of these species by immunoblotting is enhanced 
by PNGase treatment of N-linked glycans that produce a diffuse, 30-36kDa banding pattern for 
“mature” Tetherin. Interestingly, deglycosylated Tetherin blots had been analyzed prior to our 
work, including one, which identified the presence of a two species in HeLa cells. However, the 
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bands were misidentified as potential differences in post-translational modifications (6). It is 
peculiar that the human Tetherin isoforms were not discovered previously. However, it is very 
likely that prior to our study most labs did not routinely deglycosylate lysates when expressing 
Tetherin and/or used Tetherin expression vectors with either strong Kozak sequences at the first 
start site or codon optimized cDNA. These reasons would account for why this phenomenon was 
not observed. Strengthening the Kozak upstream of the putative AUG leads to almost exclusive 
expression of l-Tetherin, suggesting alternative translation initiation off a single polycistronic 
mRNA as the underlying mechanism. This presents a way by which Tetherin expression, and 
subsequent function(s), can potentially be modulated raising the question of whether endogenous 
expression of the isoforms can be regulated by different stimuli. Additionally, the heterogeneity in 
Tetherin glycosylation may be a representation of variants that could also have different cellular 
localizations; changes in Tetherin glycosylation has been shown to impact subcellular 
localization, but still allow restriction of certain viruses. 
We expanded our observation to rhesus and murine Tetherin, also observing multiple 
Tetherin species from cDNA expression further suggesting this is a conserved mechanism by a 
variety of mammalian species. Mounting evidence suggests the translation of a truncated 
regulatory Tetherin isoform is common in mammals. During the preparation of the work 
highlighted in Chapter 2, a naturally occurring polymorphism in the putative Tetherin upstream 
start codon was observed in a NZW mouse leading to expression of only the shorter isoform 
lacking the dual-tyrosine motif (17). As observed in human Tetherin, loss of the tyrosine motif 
stabilizes the protein at the plasma membrane. In a viral challenge experiment with Friend 
retrovirus, the polymorphism conferred increased protection to viral replication compared to a B6 
mouse encoding the wt tetherin sequence (17). The genomes of ruminants have been found to 
have gene duplications in Tetherin, generating proteins with tails of variable length, including loss 
of the conserved tyrosine residues. When tested against ovine or bovine specific viruses, the 
shorter forms were the more potent antiviral product (9, 225). Additionally, feline Tetherins have 
been described to have full-length and truncated tails although in the context of feline viruses 
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tested, no differences in resistance to viral challenge have been observed (50, 58). Tetherin 
isoforms identified thus far vary in surface stability, sensitivity to different viral antagonists and to 
differentially signal. It will be interesting to determine whether there are additional functional 
differences between the human Tetherin isoforms. The observation that various mammals can 
express different Tetherin species suggests an underappreciated versatility of the protein. A 
Tetherin-like molecule expressed in Chinese hamster cells called GREG (Golgi-resident GPI-
anchored protein) was shown to be involved in regulating Golgi integrity (123), a function similar 
to that of Golgins, which like Tetherin are also integral membrane coiled-coil proteins. This 
molecule resides almost exclusively in intracellular compartments, but is involved in impacting 
membrane dynamics, which may parallel what Tetherin does at the cell surface when enveloped 
viruses perturb membrane integrity.  
The dual-tyrosine is important for Tethering trafficking (140, 181). There is evidence of 
enhanced plasma membrane stability of Tetherin species that lack this motif in vitro, as well as in 
a naturally occurring mutation in NZW mice (26). These shorter Tetherin variants may be the 
most important form for restricting viral replication, which may explain why the second 
cytoplasmic methionine is highly conserved. The lack of the dual tyrosine motif in s-Tetherin 
makes it highly resistant to HIV-1 Vpu, which is thought to engage Tetherin intracellularly. 
Conversely, l-Tetherin is highly sensitive to Vpu-mediated downregulation. Along with the dual 
tyrosine motif, an upstream STS sequence, when mutated in combination produces s-Tetherin-
like, Vpu resistance in the Vpu-sensitive l-Tetherin background. Independently, both these amino 
terminal regions confer some degree of resistance to HIV-1 Vpu in virus-like particle (VLP)-based 
systems and subsequently validated with replication competent HIV-1 (247). In the context of viral 
infection, the dual-tyrosine may serve a regulatory purpose and therefore expression of full-length 
Tetherin (l-Tetherin) may be important to properly traffic and relocate the short form after viral 
particle restriction.  
 In Chapter 3 we identify the minimal mutations necessary to confer HIV-1 Vpu 
resistance, highlighting a crucial threonine at position 4 (T4). Based on our data, the flanking 
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serine residues, contribute minimally to the phenotype observe with SY. It is unclear what role 
these residues play in regulating Tetherin function. Ubiquitination of this motif has been 
suggested in the presence of Vpu, but that mechanism remains controversial (72, 229). However, 
this does not rule out the possibility of additional post-translational modifications, as serines and 
threonines can be phosphorylated and acetylated. We also do not know whether these residues 
contribute to trafficking. Because of the proximity between STS and the dual tyrosine motif, 
modifications at either serine or the threonine could sterically hinder machinery engaging the 
tyrosine residues. Phosphoproteomics has produced evidence of tyrosine phosphorylation of the 
Tetherin cytoplasmic tail (211). A similar mass-spectrometry approach could be employed to 
assess serine/threonine modifications, which may highlight a novel regulatory mechanism for 
Tetherin function. 
Co-expression of s-Tetherin affects l-Tetherin sensitivity in the presence of Vpu and 
signaling function (see below), suggesting s-Tetherin has a dominant phenotype, highlighting a 
potential regulatory role for this novel isoform. Alternative translation initiation of an in-frame 
polycistronic mRNA generating a truncated isoform with “dominant-negative” properties was 
recently described with another immune factor, mitochondrial antiviral-signaling protein (MAVS) 
(30). The IFN response to viral infection is rapid and crucial for a robust innate immune response. 
It is defined by the upregulation of a large array of genes collectively called ISGs. It is estimated 
that our genome encodes over 300 ISGs with diverse cellular localizations and functions. 
Diversification of ISGs through various transcriptional and translational mechanisms enhances 
the functional repertoire of proteins to counter a myriad of viruses that could infect the host. To 
date the subset of immune genes identified and validated as being regulated by alternative 
translation initiation is small including Tetherin, MHC class II invariant chain (220), MAVS (30) 
and osteopontin (203). The ribosome profiling analysis that identified MAVS isoforms also 
identified potential internal translation initiation sites (TISs) for several other ISGs (30) suggesting 
the use of isoforms with differential or regulatory biologic activities may be a common strategy 
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during innate immune responses. Future studies of these putative isoforms should reveal if this is 
the case. 
Expression off polycistronic mRNA is not a new concept, rather an underappreciated 
mechanism of regulating protein expression and diversity. Advances in sequencing technology 
have furthered our understanding of how prevalent this mechanism may be. Ribosomal 
footprinting assays have revealed that between 50-65% of transcripts contain more than one 
candidate TISs (34, 90, 119). However, few examples of in-frame polycistronic mRNAs have 
been identified and validated. Ribosome footprinting identified ribosome association with in-frame 
downstream AUGs predicted to produce an alternative Tetherin isoform in both human and 
murine cells, supporting our hypothesis (30, 90). Despite the footprinting studies in cultured cells 
the primary TIS for Tetherin remains unclear. Expression of truncated forms of Tetherin lacking 
the upstream dual tyrosine motif has been observed in sheep, cats, and mice (9, 17, 26, 37).  
Moreover, most upstream sequences tend to be in the context of a suboptimal Kozak. A more in-
depth analysis using ribosomal footprinting on a broad range of cell types should be employed to 
address whether there is preferential ribosomal binding at either start codon.. 
It is still unclear how, or if, Tetherin isoform expression is regulated. We don’t know 
whether there is cell-intrinsic machinery that allows one isoform to be preferentially expressed in 
one cell type versus another or if the isoforms are differentially translated under varying 
conditions. We observed that interferon alpha (IFNα) stimulation appeared to upregulate both 
isoforms equally in several cell types/lines tested, including 293T, HT1080, HeLa and primary 
CD4 T cells although these studies did not employ stringent quantification. It is unknown whether 
tetherin mRNA can form secondary structures, like hairpins, around the start sites, which could 
regulate initiation/scanning of the pre-integration complex and/or processivity of the 80S ribosome 
leading to differential protein expression.  
A common consequence of innate response to viral infection is global repression of 
translation by the host cell. This mechanism is highly effective against various viral families that 
replicate in the cytoplasm. During periods of stress eukaryotic translation initiation factor 2 (eIF2) 
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becomes phosphorylated by one of four known kinases, one of which is the IFN induced viral 
RNA sensing protein kinase R (PKR) (61). eIF2 phosphorylation leads to a reduction in active 
ribosomal complexes available for global translation. Among the proteins upregulated by this 
mechanism are those involved in certain stress responses (15). Ribosome become more 
selective and may preferentially bind one TIS over another stochastically or depending on 
sequence context. Neither Tetherin start site is in the context of an optimal Kozak; therefore it is 
difficult to predict whether one is preferred over the other. However, viral infection assays in the 
presence or absence of PKR should be done to assess whether there are changes in Tetherin 
isoform expression. Although none have been seen in human genomic analysis to date, it is 
unclear whether there exist naturally occurring polymorphisms around either start site or in the 
untranslated region of the human tetherin mRNA that could lead to changes in isoform expression 
as is seen in other mammalian species. 
Tetherin-Vpu interactions have provided invaluable insight into differential regulation and 
function of long and short isoforms.in the context of viral infection. There is clear evidence that 
certain viruses do not discriminate between various isoforms. Host-pathogen co-evolution would 
suggest that successful viruses could take advantage of Tetherin function to facilitate 
transmission. Interestingly, challenge with FIV, which utilizes its Env to counter Tetherin function, 
indiscriminately antagonizes both feline Tetherin isoforms, similar to what we have observed with 
EBOV GP. Recently, FIV has been suggested to replicate better in felid Tetherin expressing cells. 
The existence of a potent short isoform may be a critical barrier against certain viruses that 
encode antagonists that do not target the cytoplasmic tail. However, the diversity in mechanisms 
by which viruses counter Tetherin function may speak more about how viruses may take 
advantage of a particular feature of Tetherin biology for replication. This has been suggested from 
observations that Tetherin could facilitate infection (50, 89, 96, 236). Because of differences in 
surface stability we would hypothesize that Tetherin isoforms could differentially allow for cell-cell 
spread of certain viruses at virological synapses as observed with HTLV-1 and HIV-1.  
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Various poorly characterized aspects of Tetherin biology (see Chapter 1) could be 
elucidated by studying the impact of l-Tetherin or s-Tetherin in isolation. Stable cell lines encoding 
either isoform should be employed to assess potential differential roles of the Tetherin isoforms 
from various species in cell-cell spread, NK mediated killing and IFN regulation of 
immunoglobulin-like transcript 7 (ILT7), as all three would require single round infection with virus 
followed by co-incubation with target cells. We hypothesize that surface stability of s-Tetherin 
could be a double-edged sword, potentially enhancing cell-cell transmission of tethered viruses 
as previously described (50, 89, 96), but also aiding in antibody-dependent cell-mediated 
cytotoxicity (ADCC) (1, 8) by stabilizing antigen (viral particles) on the cell surface.  ILT7 on 
human pDCs negatively regulates pDC-mediated IFN expression upon interaction with Tetherin 
on the surface of IFN stimulated cells. Recently, tethered viral particles were shown to occlude 
Tetherin-ILT7 interactions.  By increasing viral tethering on the cell surface, s-Tetherin could 
potentially interfere with IFNα dampening in pDCs. In this scenario, one would hypothesize that 
the short isoform might aid in viral clearance by maintaining elevated IFN levels. Prolonged 
production, however, could have pathological consequences due to prolonged exposure. To date 
we do not have evidence of individual human Tetherin isoforms being expressed. However, we 
can take advantage of in vitro systems and murine isoform models to assess various isoform 
functions and elucidate more of the biology underlying this unique membrane anchored protein. 
Summary and perspectives on Tetherin-mediated activation of NF-κB 
Our work studying human Tetherin isoforms identified that a previously uncharacterized 
NF-κB signaling function is specific to l-Tetherin and that this function is regulated by the 
signaling-null s-Tetherin isoform (141), Therefore we initially hypothesized that the necessary 
signaling determinants would localize to first 12 amino acids of the Tetherin cytoplasmic tail. We, 
and others, discovered that the dual-tyrosine trafficking motif was an important determinant of 
NF-κB activation (44, 59, 228). Our preliminary rationale was that the tyrosine-based trafficking 
motif resembled an ITAM-like sequence therefore potentially serving dual function. A whole cell 
phosphotyrosine proteomics analysis demonstrated that Tetherin could be phosphorylated (211). 
       102 
In Chapter 3 we continued to build on understanding Tetherin-mediated signaling through 
mutational analysis of the Tetherin cytoplasmic tail. Work from the Neil and Guatelli groups, 
published during the time we were conducting the studies highlighted in Chapter 3, described 
additional structural determinants of Tetherin-mediated signaling. Compilation of these data has 
led to the  current model signaling model where Tetherin can sense viral assembly and budding 
(59, 228). However, our work has yielded some results that do not agree with the current model 
of Tetherin-mediated signaling.  
 We identified a Tetherin mutant (SY Tetherin) that can activate NF-κB independent of the 
dual tyrosine motif, which challenges the current model that Tetherin-mediated signaling through 
NF-κB occurs via a hemITAM motif. Substitutions at both cytoplasmic tyrosines in combination 
with changes in the  serine-threonine-serine (STS) region at the amino terminus of the Tetherin 
cytoplasmic tail previously described in Chapter 2 to contribute resistant to HIV-1 Vpu, allow 
Tetherin to retain signaling function. In Chapter 3 we identify a single alanine substitution 
threonine 4, T4A as sufficient to restore signaling function in the dual tyrosine mutant background 
mirroring the effect of this mutant upon Vpu resistance. To assess the contribution of additional 
individual residues to NF-κB activation, we engineered cytoplasmic tail point mutants in the l-
Tetherin background to assess contributions of additional individual residues. We observed 
mutation at tyrosine 6 to alanine, Y6A, abrogated signaling while Y8A had no effect, confirming 
what had been seen in the wt Tetherin background (60). Interestingly, in their triple alanine 
substitutions, Galao et al. observed signaling function for mutations at residues 4-6 which 
includes T4, S5 in combination with the loss of Y6, paralleling what we see with the dual tyrosine 
motif mutant (59). Conservative phenylalanine substitutions revealed that Y6F, unlike Y6A, still 
retained the ability to activate NF-κB. Though the dual tyrosine mutant FxF had abrogated 
signaling, it is unclear whether the overlapping tyrosines are redundant in function. In the case of 
trafficking, both must be mutated to produce aberrant localization (140, 181).  
We assessed whether additional point mutations could abrogate Tetherin signaling. We 
generated various point mutants in the l-Tetehrin background, highlighting individual residues 
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across the entire cytoplasmic tail to be important via alanine scanning mutagenesis. Y6 and R19 
alone had the most drastic effect, and had also been also observed to be important (60, 191). We 
also identified the importance of position 2. We generated two mutations, a conservative A2V and 
a charged A2E, ensuring the Kozak context around the putative start codon was not disrupted. 
Both mutants failed to signal. A2V, specifically, expressed primarily lower molecular weight 
products suggesting stability was an issue. In the context of position 2, N-terminal processing of 
the start methionine is common. N-terminal acetylation has been suggested to play a role in 
protein stability and localization (10). N-terminal processing predictive software suggests wt 
Tetherin and A2E mutant can be potentially be N-acetylated, but not A2V (146). Peptides isolated 
from the phosphoproteomics screen also identified the wt cytoplasmic tail peptide as being N-
terminally acetylated at A2 (211). 
  Direct phosphorylation of the Tetherin cytoplasmic tail at both tyrosines has been 
observed in peptides isolated from a phosphoproteomics screen (211). There is a correlation 
between signaling competent Tetherin and ability to immunoprecipitate with an anti-
phosphotyrosine (pY) Ab. However, immunoprecipitation (IP) and co-IP data suggesting that 
phosphorylation of Tetherin mediates recruitment of Syk via a hemITAM motif does not 
necessarily show a direct interaction. To test a direct interaction between Syk and Tetherin, 
synthesized Tetherin cytoplasmic tail peptides with phosphotyrosine modifications could be 
produced, immobilized and tested by surface plasmon resonance (SPR). Syk specific binding has 
been assessed for CLEC-2 by SPR (88). Swapping the Tetherin tyrosine motif into another 
hemITAM containing molecule could also be employed test its ability to act as a bona fide 
immunotyrosine-based motif. Swapping the entire human Tetherin cytoplasmic tail onto Tetherin 
proteins from another species does not activate NF-κB  (59), though the scaffold used in the 
study was rhesus Tetherin which has a two amino acid deletion in the TM domain identified as a 
determinant for signaling (59). It is unclear whether adding the tail to a heterologous protein with 
similar properties as Tetherin (e.g. type II TM, dimerizes, localizes to lipid-rafts) could be enough 
to confer function. We would predict that if Tetherin is signaling indirectly through Syk, we could 
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still use pY Abs to IP our signaling competent SY mutant. This finding would suggest the need for 
an adaptor molecule that could bind Tetherin elsewhere on the tail or through a different domain 
to activate signaling. 
Tetherin was identified as a PRR sensing viral assembly and budding (59, 228). 
Determining whether SY can activate signaling by sensing particle release is important to 
strengthen our working hypothesis that Tetherin is not directly recruiting Syk via a hemITAM. The 
interaction between Tetherin and RICH2 has been shown to be important for signaling through 
actin-mediated activation of Src kinases, which are believed to phosphorylate the hemITAM-like 
sequence. However, RICH2 can bind non-signaling Tetherin variants such as the dual tyrosine 
mutant equally well (60). The only mutant identified to have very poor binding was a mutant at 
R19, which we also observed to be signaling deficient. Based on this observation we would 
predict that SY would bind RICH2. We have demonstrated that TAK1 can co-IP with the SY 
mutant as has been observed with wt Tetherin (59, 228). Additionally, both Src-family and Syk 
kinase specific inhibitors dampened SY-induced signaling in a dose dependent manner 
suggesting both kinase families are at least indirectly involved in Tetherin mediated NF-κB  
activation. Additional perturbation of both pathways using siRNA against Syk and inhibitors 
against TAK1 should be done to confirm our observations and strengthen the model that does not 
involve a hemITAM. 
Additional mutations in the STS region of the cytoplasmic tail of Tetherin suggests 
Tetherin phosphorylation could be important for stabilizing a conformational change within 
Tetherin rather than directly recruiting Syk. We believe this may be the underlying mechanism 
regulating Tetherin mediated signaling. Acidic mutations in the l-Tetherin background abrogate or 
significantly impair signaling, with the exception of the tyrosine proximal serine S5, which is 
reduced but not to basal levels. This may explain why A2E also decreased signaling. The STS 
region is thought to be under selective pressure in primates. Interestingly swapping STS with the 
rhesus sequence PIL abrogates signaling. An S5L substitution, which makes the STS region 
more like chimp or gorilla Tetherin retains signaling function, and may actually increase activity. 
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These two observations, including an apparent S5L enhancement in signaling, were previously 
made in the wt background (157). To our surprise, introducing S5L into the dual-tyrosine motif 
mutant restores signaling. Leucine hydrophobicity may be playing a role. Additionally, a series of 
polyalanine mutations can be engineered across the entire l-Tetherin specific region of the tail, 
still allowing l-Tetherin to retain transient signaling function. Taken together, neutrally charged, 
hydrophobic mutations upstream of the dual-tyrosine motif, but not charged or structure altering in 
the case of proline from PIL allow Tetherin to signal, suggesting an important and 
uncharacterized regulatory function for this STS region. 
Phosphorylation of the tyrosine residues in the wt Tetherin cytoplasmic tail could lead to a 
conformational change(s) rather than direct recruitment of Syk kinase (Figure 5-2). The various 
tyrosine independent, signaling-competent mutants described in Chapter 3 may be primed in a 
conformation that facilitates NF-κB activation, mimicking what is observed during wt Tetherin 
signaling. We observe that SY Tetherin constantly induces higher levels of NF-κB  activation 
compared to the l-Tetherin parent. We speculate that a primed Tetherin could access signaling 
machinery faster without the need of an activation event, like phosphorylation for example. 
However, we do know that SY signaling can be regulated and does not have a dominant 
phenotype, at least in the presence of s-Tetherin, as seen in the titration experiments and with 
expression of SY in the wt background. The main difference between l- and s-Tetherin is the 
length of the cytoplasmic tail. Interaction between the juxtaposed tails of Tetherin isoform 
heterodimers (or tetramers) expressed on the cell surface could be important to signaling. One 
possible conformational change is enhanced dimerization of the tails, due to a more coiled and 
hydrophobic amino identity as a result of the substitutions. In the hemITAM model, Syk kinase 
could be doing the same thing if we are to believe it is functioning as Syk has been suggested to 
do with CLEC-2 (87). The SH2 domain of Syk or some other SH2 domain containing kinase could 
bridge phosphotryrosine residues from adjacent tails bringing the two together. Though our drug 
data suggests Syk is still being recruited by some indirect means, this does not rule out the 
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possibility that another unknown kinase like PI3 kinase, which has been proposed to interact with 
hemITAM motifs and regulate downstream Syk function, could be involved upstream (135). 
Enhanced membrane recruitment of the Tetherin cytoplasmic tail could be a possible 
mechanism since hydrophobicity has been shown to be important. A recent report described 
naturally occurring equine Tetherin proteins that activate NF-κB  in a tyrosine-independent 
manner (259). Interestingly, these Tetherins have very short cytoplasmic tails, comparable in 
length to s-Tetherin. How do these Tetherins activate signaling in the absence of signaling motif? 
A simple explanation could be that there is an unidentified motif present. Alternatively, signaling 
observed by equine Tetherin is occurring through an alternative mechanism compared to human 
Tetherin. Horse and donkey Tetherin both have a glycine present at position 2 which may 
suggest the possibility of these equine Tetherin could be lipidated. Addition of a lipid modification, 
like myristoylation, onto these short Tetherin species could enhance membrane targeting. The 
myristoylation signal sequence is not optimal compared to the consensus, though there are 
examples of myrisoylated proteins that have non-consensus signal sequences.  
Tetherin has a membrane proximal basic residue, which could stabilize membrane 
interactions with the negatively charged heads on plasma membrane lipids localized to the inner 
leaflet (Figure 5-2B, C). R19 mutants abrogate signaling, and additional single alanine scanning 
in that region suggests the lysines in the KRCK membrane proximal region could also play a role. 
Increased hydrophobicity observed in our tyrosine-independent mutants may target the human 
Tetherin cytoplasmic tail to the inner leaflet of the plasma membrane similar a lipid moiety (Figure 
5-2C).   Acidic residue introduced in this region could repel those interactions explaining why we 
did not observe activation. Secondary structure analysis using predictive software suggests turn-
like structure was identified around Y6 using NetTurnP predictive software (173). Secondary 
structure predictor suggests coil structures at both ends of the tail (Figure 5-1). (174), The region 
in between is predicted to be less structured extended strand (63). The coiled nature increases 
with increasing alanine mutations correlating with signaling function. This leads us to predict that 
the Tetherin cytoplasmic tail may exist in an inactive state associated with RICH2. Upon 
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phosphorylation Tetherin may undergo a conformational change (and possibly additional 
modifications), which could mediate membrane targeting. Biophysical assays could provide 
insight in determining the dynamics of the Tetherin cytoplasmic tail during signaling as well as the 
extent of membrane interactions. Additionally, assessing membrane insertion of SY and 
polyalanine Tetherin tails into artificial membranes could suggest membrane interaction in vivo. 
As stated earlier, signaling machinery could potentially bind Tetherin on some other part 
of the protein, including the second half of the cytoplasmic tail, the TM domain or the GPI-
anchored end as possible candidates for mediating signaling. GPI-anchored proteins, which don’t 
access the cytoplasm, have been demonstrated to signal in various immune contexts primarily in 
lymphocytes (213). The role of the Tetherin GPI-anchored has been debated (25, 60, 228). 
Billcliff et al. have discussed Tetherin within the context of the “picket fence” model of membrane 
organization (25). The “picket fence” model suggests Tetherin can organize these microdomains 
and upon clustering can coalesce domains, which increases the size and density of the raft 
domains (Figure 1-3B). A recent publication suggests the outer membrane actually exists in a 
uniform fluid state and that GPI anchored proteins play a role in limiting lateral diffusion through 
steric hindrance (199) and thus could maintain the integrity of protein composition in we describe 
as microdomains. Tetherin, which sits both in and out of raft domains via a GPI anchor and 
transmembrane domain, respectively, possess this trait as knocking down Tetherin expression 
has been associated with increased diffusion of proteins and disruption of the underlying actin 
cytoskeletal network ((25, 180). Rafts are known to be sites of signaling platforms, and Tetherin 
could be involved in increasing the density to where it and viruses localize when egressing. We 
propose that SY could potentially bring microdomains into closer proximity while also stabilizing of 
signaling platforms (Figure 5-2D).  
Tetherin-mediated signaling has many implications, not only during viral replication, but 
also potentially for normal and dysregulated cell biology. Tetherin signaling in cell culture has 
been a useful tool to elucidate mechanism, however the consequences of Tetherin mediated 
activation in vivo are not clear. Tetherin can enhance immune responses in mice (122). However, 
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whether this function is dependent on Tetherin-mediated activation of NF-κB  is unclear. To 
assess the role of Tetherin-mediated signaling in vivo, a humanized mouse model would need to 
be developed. Tetherin knockout mice have been generated without gross developmental effects 
(124, 223). However, in cell culture, murine Tetherin does not activate NF-κB, a caveat being that 
the experiments were performed in human cells. The NF-κB pathway is well conserved which 
suggests murine Tetherin lacks this function. Identifying whether signaling function is conserved 
among different Tetherins in their cognate cells would be important to translate cell culture 
systems into animal models. 
Another aspect of Tetherin signaling that is unclear is how similar are the three methods 
utilized to asses NF-κB activation. Parallel profiles of cytokines have not been assessed. 
Transient expression has served as a good tool to streamline various mutants, while crosslinking 
facilitates kinetic studies. We currently assume particle tethering, crosslinking, and transient 
overexpression via transfection are initiating NF-κB activation via the same mechanism. Tetherin 
appears to sense budding particles, but in the absence of viral replication, could this property also 
be useful during normal cell biology. Tetherin has been suggested to be upregulated in various 
malignant and invasive cell types, though it is unclear what role Tetherin may play. NF-κB 
dysregulation has been attributed to various types of cancers and it is tempting to speculate 
Tetherin signaling could be somehow be contributing to cell survival, growth and invasion. 
Assessing the growth and metastatic nature of cancer cells in the presence and absence of 
Tetherin could provide some insight. Taken together, there are still pertinent questions about, 
mechanistically, how Tetherin is signaling, as well as what are the implications of this function. 
We believe much of the machinery that has been implicated plays an important role, but our 
findings suggest signaling may be more nuanced then previously thought.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1. Compilation of secondary structure analysis of Tetherin cytoplasmic tail. 
Alignment of Tetherin sequences for representative mutants from Chapter 4 mutational analysis. 
Predictive secondary structure for cytoplasmic tail denoted under sequence. Length of predictive 
structure highlighted by black bar. GOR4 Secondary Structure Prediction Method was used to 
identify coiled regions. NetTurnP was used to predict beta-turns. Activation level by each Tetherin 
qualitatively represented by number of plus symbols: WT signaling = ++.  - = signal-deficient. ExE 
is a phospho-mimetic which has not been tested for signaling (Only predicted structure assessed) 
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Figure 5-2. Our proposed model for Tetherin-mediated signaling. Tetherin exists as a dimer 
on the cell surface. (A) The cytoplasmic tails are in a “closed” conformation, preventing signaling 
machinery from engaging. (B) The open conformation may bind signaling machinery directly, 
downstream of the dual-tyrosine motif. Tyrosine phosphorylation is likely involved in generating 
this active state. This interaction may be sufficient to propagate signaling (C) Positive residues in 
the tail that are membrane proximal could facilitate interactions with the negatively charged inner 
leaflet of the membrane allowing close proximity with machinery that reside in lipid rafts (D)  
Alternatively, the Tetherin tail may insert into the membrane allowing Tetherin inhabited 
microdomains to come in close proximity (arrow), brining signaling machinery together indirectly 
to initiate signaling 
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APPENDIX- LIST OF ABBREVIATIONS 
Ab –antibody  
APC- antigen presentation cell 
EBOV – ebolavirus  
ER – endoplasmic reticulum 
ESCRT – endosomal sorting complexes required for transport 
Env – envelope glycoprotein 
GP - glycoprotein 
GPI anchor – glycophosphatidylinositol anchor 
HIV-1 – human Immunodeficiency virus 1 
IFN – interferon 
IP - immunoprecipitation 
IRF – interferon regulatory factor 
ISG – IFN stimulated gene 
ITAM – immunotyrosine-based activation motif 
JAK/STAT - Janus kinase/signal transducer and activator of transcription 
l-domain – late budding domain 
MVBs – multivesicular bodies 
NF-κB – nuclear factor kappa-light chain-enhancer of activated B cells 
ORF – open reading frame 
PM – plasma membrane 
PRR – pattern recognition receptor 
RLRs – RIG-I-like receptors  
SIV – simian immunodeficiency virus  
TGN – trans-Golgi network 
TIS – translation initiation site 
TLR(s) – Toll-like receptor(s)  
TM – transmembrane 
VLP(s) – virus-like particle(s) 
Vpu – viral protein U 
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